Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Diffuse cutaneous systemic sclerosis
Diffuse cutaneous systemic sclerosis
Diffuse cutaneous systemic sclerosis
Synonyms: Diffuse cutaneous systemic scleroderma, Progressive cutaneous systemic scleroderma, Progressive cutaneous systemic sclerosis
Synonyms: Diffuse cutaneous systemic scleroderma, Progressive cutaneous systemic scleroderma, Progressive cutaneous systemic sclerosis
Synonyms: Diffuse cutaneous systemic scleroderma, Progressive cutaneous systemic scleroderma, Progressive cutaneous systemic sclerosis
Drug discovery
8
drugs
With orphan designations
Rare systemic or rheumatologic diseases
Diffuse cutaneous systemic sclerosis
Overview
Diffuse cutaneous systemic sclerosis (dcSSc) is a severe subtype of systemic sclerosis characterized by rapid, widespread skin fibrosis (typically affecting arms, trunk, and face) and early multi-organ involvement, including interstitial lung disease, renal crisis, gastrointestinal dysmotility, and cardiac complications. Associated with anti-Scl-70 antibodies, it progresses faster than limited forms, with a 10-year survival rate of 60–80% due to life-threatening organ damage [1][4][6].
Population
Prevalence: ~1/25,000 adults, predominantly affecting women (4:1 female-to-male ratio) [1][12].
Demographics: Higher incidence in African American individuals, who often present younger with more aggressive organ involvement [2][12].
Autoantibodies: Anti-topoisomerase I (Scl-70) positivity in 30–40% of cases [1][7].
Burden
Mortality: Leading causes include pulmonary fibrosis (60% of cases), renal crisis (15–20%), and cardiac complications [1][4][15].
Treatment burden: Average 10 tablets/day, frequent discontinuations due to side effects [5][9].
Quality of life: Profound impact from skin tightening, pain, fatigue, and loss of independence; 27% report fecal incontinence [5][16].
Therapies
Immunosuppressants: Methotrexate, mycophenolate mofetil, or cyclophosphamide for skin fibrosis and lung involvement [8][13][17].
Organ-specific therapies: Calcium channel blockers (Raynaud’s), proton pump inhibitors (gastroesophageal reflux), and pulmonary vasodilators (pulmonary hypertension) [1][6].
Emerging options: Autologous stem cell transplantation for rapidly progressive cases [13].
Categories: rare cardiac diseases, rare renal diseases, rare respiratory diseases, rare skin diseases, rare systemic and rheumatological diseases, rare systemic or rheumatologic diseases of childhood, rare transplant-related disorders
Research Papers
1,097 drug discovery papers about Diffuse cutaneous systemic sclerosis, with 1 first-in-class and 36 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,097 drug discovery papers about Diffuse cutaneous systemic sclerosis, with 1 first-in-class and 36 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
proteins
2026-08-07 | Pyruvate kinase M2 is elevated in systemic sclerosis and plays a role in its pathogenesis.
Systemic sclerosis is an autoimmune fibrotic skin disease characterised by immune activation and fibrosis. Fibroblasts are at the core of this fibrotic process, differentiating into effector myofibroblasts; however, the drivers of this process remain obscure. Recently, metabolic changes in cells in fibrotic diseases have been uncovered, with changes in the TCA cycle and glycolysis being observed. The objective of this work was to elucidate the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in systemic sclerosis. Serum from early diffuse systemic sclerosis (SSc) patients and healthy controls (HC) was collected for PKM2 analysis by ELISA. Fibroblasts were isolated from HC and SSc biopsies and treated with transforming growth factor-beta 1 (TGF-β1) to assess PKM2 expression. PKM2 was pharmacologically modulated, and collagen and Extracellular Matrix (ECM) regulators were evaluated. Metabolic activity was assessed using Seahorse assays, and lactate transport was chemically inhibited. Chromatin immunoprecipitation was performed using a histone lactylation-specific or isotype antibody, and lactate or acetate supplementation experiments were conducted. We found significantly elevated circulating and fibroblast PKM2 in SSc patients. Fibroblast PKM2 could be induced in healthy fibroblasts by TGF-β1 exposure. Furthermore, PKM2 drives a metabolic shift to glycolysis that can be blocked by forced tetramerisation of PKM2 from its dimeric form; this resulted in reduced ECM and matrix regulators. Mechanistically, PKM2-mediated glycolysis results in elevated lactate, which drives collagen via epigenetic regulation by histone H3K18 lactylation. Blockade of PKM2 dimerisation reduced Histone H3 at Lysine 18 (H3K18) lactylation at the collagen promoter, which could be restored with lactate but not acetate. We further demonstrated that lactate-induced collagen is partially mediated by HIF-1α. PKM2 drives activation of fibroblasts in SSc via metabolic changes such as glycolysis. Taking advantage of PKM2 tetramerisation or blockade of lactate generation could be a possible therapeutic option in a disease with few treatment options.
2026-02-11 | Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis.
The study elucidates the impact of the programmed cell death protein 1 (PD-1) pathway on immune activation and fibrosis in diffuse cutaneous systemic sclerosis (dcSSc). We obtained blood and skin biopsies from patients with dcSSc and healthy controls (HCs). Soluble PD-1 was measured in serum. Human recombinant PD-1 protein (PD-1:Fc) and anti-PD-1 antibodies were used to stimulate peripheral blood mononuclear cells (PBMCs), HC, and systemic sclerosis (SSc) dermal fibroblast cultures, and cocultures. PD-1-positive (PD-1pos) and PD-1-negative (PD-1neg) populations of dcSSc PBMCs were characterised. We used a murine bleomycin model of pulmonary injury to study the effect of PD-1:Fc on pulmonary fibrosis in vivo. Soluble and cellular PD-1 were elevated in dcSSc compared to HC. Naïve fibroblasts differed between HC and dcSSc, but did not respond to PD-1:Fc treatment. Transforming growth factor β (TGF-β)-stimulated fibroblasts from dcSSc displayed a myofibroblast profile with a differential clustering compared to HC fibroblasts. PD-1:Fc downregulated the secretion of extracellular matrix (ECM) proteins, surface markers of fibroblast activation, and the production of inflammatory cytokines in TGF-β-stimulated in vitro cultures. PD-1pos SSc T cells had a different and more regulatory transcriptional profile than the PD-1neg T cell population. In vivo studies demonstrated that treatment with PD-1:Fc inhibited the development of lung fibrosis and the production of profibrotic cytokines. Administrating PD-1:Fc attenuated inflammation and ECM protein production in dcSSc in vitro models and decreased systemic inflammation and pulmonary fibrosis in the bleomycin-induced fibrosis model in mice. Our data indicate that modulating the PD-1/PD-Ligand 1 axis represents a novel therapeutic avenue in dcSSc.
2025-04-01 | P130 Prolonged treatment with novel cyclical RP peptides reprogrammes M2 macrophages towards a resolving phenotype in diffuse cutaneous systemic sclerosis
Abstract Background/Aims Alternatively activated (M2) macrophages are believed to promote pathological fibrosis and represent a potential therapeutic target in fibrotic diseases including systemic sclerosis (SSc). Novel 10 amino acid therapeutic peptides targeting M2 macrophages, via binding to the CD206 receptor, represent promising therapeutics by reducing macrophage-stimulated fibrosis in tissue culture and mouse model systems. In this study, we investigate the potential for prolonged treatment with novel cyclical variants of the RP peptides to reprogramme pathogenic SSc macrophages to a pro-resolving phenotype. Methods Macrophages were derived from peripheral blood monocytes in the presence of M-CSF (4ng/ml) for 7 days from patients with diffuse cutaneous SSc (dcSSc) and healthy controls (n=3 dcSSc and 1 HC). On day 7, 9 and 11, macrophages were treated with 10µM of RP peptide (cyclical RP606-30, or comparator RP; RP class) or left untreated in n=6 replicates per treatment group. On day 14, media were removed and cells were collected, washed, lysed for RNA extraction, and profiled by qPCR for CD206 (pro-fibrotic M2-macrophage marker), CD86 (pro-inflammatory M1-macrophage marker) and MERTK (pro-resolution regulatory efferocytosis marker), relative to the reference gene TBP. The ratios of CD86/CD206 were used to assay pro-inflammatory vs. pro-fibrotic and MERTK/CD206 for pro-resolution vs. pro-fibrotic phenotypes. Results For individual patients with dcSSc, cyclical RP606-30, but not comparator RP, reduced CD206 expression (Patient 1: 5.74 vs. 4.10, p=NS; Patient 2: 7.38 vs. 3.92, p = 0.014; Patient 3: 2.17 vs. 0.26, p = 0.021, relative expression level untreated vs. RP606-30) and enhanced the ratio of MERTK/CD206 (Patient 1: 0.22 vs. 0.35, p=NS; Patient 2: 0.18 vs. 0.31, p = 0.0007, relative expression untreated vs. RP606-30). Similar effects were seen in healthy control macrophages treated with RP606-30, with a significant decrease in relative CD206 expression (p = 0.012), and increase in both the MERTK/CD206 (p < 0.0001) and CD86/CD206 (p < 0.0001) ratios. Combining data for dcSSc macrophages indicated that CD206 expression was reduced with RP606-30 treatment compared to no treatment (mean ± SEM: 2.76 ± 0.51 vs. 5.06 ± 0.73, p = 0.079), and MERTK expression was slightly increased (1.24 ± 0.07 vs. 1.13 ± 0.17, p = 0.809). Compared to untreated cells, RP606-30 treatment significantly increased both the CD86/CD206 (M1/M2) ratio (2.04 ± 0.34 vs. 0.86 ± 0.22, p = 0.0036) and MERTK/CD206 ratio (0.33 ± 0.03 vs. 0.20 ± 0.03, p = 0.016). Conclusion We found that prolonged treatment with RP606-30, a cyclical RP peptide, reduced relative CD206 expression, and significantly increased the CD86/CD206 (M1/M2) ratio and the MERTK/CD206 ratio in macrophages derived from patients with dcSSc. These findings indicate that RP peptides reprogramme macrophages from a pro-fibrotic towards a pro-resolution phenotype. To further characterise the phenotypic changes involved in the polarisation of macrophages towards this pro-resolving phenotype, we plan to assay the media for levels of pro-resolving lipid metabolites (LXA4 and RvD1). Disclosure J. Mendall: None. B. Ahmed Abdi: None. K. Shetty: None. S. Lopez Garces: None. V. Ong: None. C. Denton: None. D. Abraham: None. C. Yates: Corporate appointments; Scientific Officer Riptide. J. Jaynes: Corporate appointments; Scientific Officer Riptide. H. Lopez: Corporate appointments; CEO of Murigenics. G. Martin: Corporate appointments; Senior Scientific Officer Riptide. R.J. Stratton: None.
2024-07-26 | The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis.
Systemic sclerosis (SSc) is an autoimmune connective tissue disease with a triad of features that include vascular abnormalities, inflammation and skin and lung fibrosis. At the core of the disease is the activation of myofibroblasts from quiescent fibroblasts and this can be modified by various cytokines. IL-41 is a recently described cytokine that was initially characterised as an adipokine as it was highly expressed in adipocytes and adipose tissue. However, it has recently been identified as being widely expressed and has immunomodulatory functions. This study examined the circulating levels of IL-41 and its expression in skin biopsies. We demonstrated significantly reduced levels of IL-41 in diffuse SSc that was also mirrored in the skin of SSc patients. AMPK has been proposed as a downstream target of IL-41, so we also measure mammalian target of rapamycin in skin and found that this is elevated in SSc patients. We speculate that IL-41 maybe an antifibrotic cytokine and its reduction may facilitate the activation of fibroblasts.
2024-06-01 | Interferon-γ Induces Interleukin-6 Production and Alpha-smooth Muscle Actin Expression in Systemic Sclerosis Fibroblasts.
Systemic sclerosis (SSc) is an autoimmune systemic disease that is characterized by immune dysregulation, inflammation, vasculopathy, and fibrosis. Tissue fibrosis plays an important role in SSc and can affect several organs such as the dermis, lungs, and heart. Dysregulation of interferon (IFN) signaling contributes to the SSc pathogenesis and interferon regulatory factor 1 (IRF1) has been indicated as the main regulator of type I IFN. This study aimed to clarify the effect of IFN-gamma (-γ) and dexamethasone (DEX) on the IRF1, extracellular signal-regulated kinase 1/2 (ERK1/2), and the expression of alpha-smooth muscle actin (α-SMA) in myofibroblasts and genes involved in the inflammation and fibrosis processes in early diffuse cutaneous systemic sclerosis (dcSSc). A total of 10 early dcSSc patients (diffuse cutaneous form) and 10 unaffected control dermis biopsies were obtained to determine IFNγ and DEX effects on inflammation and fibrosis. Fibroblasts were treated with IFNγ and DEX at optimum time and dose. The expression level of genes and proteins involved in the fibrosis and inflammation processes have been quantified by quantitative real-time PCR (RT-qPCR) and western blot, respectively. IFNγ could up-regulate some of the inflammation-related genes (Interleukin-6; IL6) and down-regulate some of the fibrosis-related genes (COL1A1) in cultured fibroblasts of patients with early dcSSc compared to the untreated group. Besides, it has been revealed that IFNγ can induce fibroblast differentiation to the myofibroblast that expresses α-SMA. Concerning the inhibitory effect of IFNγ on some fibrotic genes and its positive effect on the inflammatory genes and myofibroblast differentiation, it seems that IFNγ may play a dual role in SSc.
small molecules
2026-09-04 | Methotrexate Versus Mycophenolate Mofetil as First-Line Therapy in Systemic Sclerosis: Evidence from Clinical Trials and Real-World Studies—A Narrative Review
Systemic sclerosis (SSc) is a heterogeneous autoimmune connective tissue disease characterized by immune activation, vasculopathy and progressive fibrosis of the skin and internal organs. Immunosuppressive treatment is commonly used in early inflammatory disease and in SSc-associated interstitial lung disease (SSc-ILD), yet the optimal first-line agent depends on the dominant clinical phenotype. Methotrexate (MTX) and mycophenolate mofetil (MMF) are two widely used conventional immunomodulatory options. This review summarizes the clinical trial evidence from the last four decades and places it into the context of contemporary guideline recommendations and real-world comparative effectiveness data. Two randomized placebo-controlled trials support a modest role for MTX in early diffuse cutaneous SSc, particularly for skin and musculoskeletal manifestations, but evidence for lung benefit is limited. MMF has stronger evidence for SSc-ILD, principally from the Scleroderma Lung Study II, a randomized double-blind trial showing comparable efficacy to oral cyclophosphamide with better tolerability, and from subsequent pilot, open-label, and real-world studies. Overall, the current evidence supports a phenotype-driven approach: MTX may be considered when skin or joint disease predominates without clinically relevant ILD, whereas MMF is generally preferred for SSc-ILD and systemic inflammatory disease. Direct head-to-head MTX versus MMF trials are lacking and remain an important research priority.
2026-09-03 | A compact five-gene immuno-fibrotic profile distinguishing systemic sclerosis subtypes with PXDN validated as a fibrosis-associated target.
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterized by a paucity of reliable biomarkers for accurate diagnosis and subtype stratification. The considerable clinical variability between diffuse and limited cutaneous subtypes underscores an urgent need for molecular tools that can dissect this heterogeneity and guide therapeutic strategies. To address this, we employed a multi-step computational approach. Initially, Weighted Gene Co-expression Network Analysis (WGCNA) was applied to the GSE130955 dataset to identify disease-associated modules. This was followed by the application of three machine-learning algorithms-LASSO regression, random forest, and SVM-RFE-to the GSE181549 dataset for hub gene selection. Immune cell infiltration was estimated using CIBERSORT, and the expression of candidate genes was validated at single-cell resolution using the GSE138669 dataset. Experimental validation was performed for the top candidate, PXDN, assessing its protein expression in human fibroblasts, SSc patient skin, and a bleomycin-induced murine fibrosis model. Finally, molecular docking with AutoDock Vina was conducted to evaluate the binding affinity of small molecules to PXDN. WGCNA identified a module strongly correlated with SSc status (r = 0.73, p < 2e-16), which was enriched in immune chemotaxis and extracellular matrix organization pathways. The convergence of the three machine-learning algorithms nominated a five-gene signature (CPXM1, ELN, GSTM5, PXDN, PDE7B), which demonstrated high diagnostic accuracy (AUC = 0.985, 95% CI: 0.965-1) and effectively distinguished diffuse from limited cutaneous SSc. Single-cell analysis confirmed predominant expression of these genes in fibroblast and macrophage populations within SSc lesional skin. Experimentally, PXDN was found to be upregulated by TGF-β1 in human fibroblasts and was significantly elevated in skin and lung tissues from SSc and IPF patients, as well as in the bleomycin-induced mouse model. Although molecular docking nominated Protokylol hydrochloride as a compound satisfying distal-cavity geometric criteria, this serves as a hypothesis-generating finding rather than a confirmed inhibitor. Our integrative analysis identifies a concise immunofibrotic gene signature that robustly distinguishes SSc and its major subtypes. This signature highlights a potential nexus of immune-stromal interactions that may underlie disease heterogeneity, offering candidate biomarkers for molecular stratification and therapeutic targeting. Notably, PXDN emerges as a particularly promising target, warranting further experimental investigation to validate its functional role and therapeutic potential in SSc.
2026-08-26 | Glucocorticoid-Minimizing Triad Therapy (T-D-M) for Early Progressive Diffuse Cutaneous Systemic Sclerosis: An Immunopathological Protocol for Pre-Fibrotic Interception and 12-Month End-Organ Damage Prevention.
Background & Clinical Paradigm Shift: Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by a narrow, critical therapeutic window of opportunity: the early edematous and inflammatory phase spanning months 0 to 15 from the onset of the first non-Raynaud symptom. Standard clinical practice frequently succumbs to therapeutic inertia, initiating intensive disease-modifying therapies only after extensive dermal collagen deposition and fixed visceral fibrosis have taken hold. Furthermore, the administration of moderate-to-high dose glucocorticoids (≥ 15 mg/day) for acute soft tissue inflammation represents the single most potent risk factor for precipitating a catastrophic Scleroderma Renal Crisis (SRC). Clinicians urgently require an objective risk-stratification matrix to predict rapid organ progression and justify aggressive intervention during the reversible, pre-fibrotic stage, utilizing ultra-low-dose glucocorticoid bridging solely to ensure infusion safety. The EPOD-SSc Scoring Matrix: We introduce the Early Progressive Organ Damage in Systemic Sclerosis (EPOD-SSc) matrix, evaluated strictly as a prerequisite within the first 15 months of disease onset. This heuristic matrix scores four high-risk domains: High-Risk Serology (Max +2), Inflammatory Dermal & Musculoskeletal Kinetics (Max +3), Microvascular Angiopathy (Max +2), and Pre-Fibrotic Visceral Inflammatory Markers (Max +2). A cumulative score of ≥ 5 identifies a highly aggressive phenotype, logically and ethically justifying the immediate execution of the Glucocorticoid-Minimizing T-D-M Triad Protocol. Architecture of the T-D-M Protocol: The protocol encompasses three pillars: T - Therapeutic Plasma Exchange (TPE): Days 1–7 (3 sessions) to rapidly clear circulating autoantibodies and profibrotic cytokines. D - Ultra-Slow Rituximab Depletion: Days 10 and 24, administered under an ultra-low-dose steroid safety umbrella (50 mg IV hydrocortisone) to preempt cytokine release syndrome without triggering SRC. M - Mycophenolate Mofetil (MMF) Maintenance: Initiated at Week 4 for sustained long-term lymphocyte suppression. Conclusion: By establishing a definitive 15-month prerequisite window and predicting rapid organ progression, this protocol delineates a clinically actionable, translational pathway to halt disease progression prior to the onset of irreversible structural scarring, safely bridging pathogenic clearance with long-term organ preservation.
2026-08-01 | Systemic Sclerosis Induced by Immune Checkpoint Inhibitors from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO): A Case Series
Objectives Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, improving outcomes in multiple advanced malignancies. Their use is often limited by immune-related adverse events (irAEs), including rare rheumatic irAEs, such as ICI-induced systemic sclerosis (ICI-SSc). Compared to idiopathic SSc, ICI-SSc typically presents with fewer extra-cutaneous manifestations and negative serologies, but data remains limited.[1] This case series describes the clinical presentation, management, and outcomes of patients with ICI-SSc to guide clinicians in balancing autoimmune toxicities with cancer control. Methods A retrospective chart review was conducted on 7 adults diagnosed with systemic sclerosis following ICI exposure between March 2021 and August 2025. All patients were referred to a Canadian academic rheumatology clinic specializing in Immuno-Oncology during ICI therapy. Clinical data was abstracted from medical records, including patient demographics, malignancy type and stage, ICI type and duration, clinical features, serologies, treatment, and outcomes. Results Of the 7 patients identified, 5 (71.4%) were female and 2 (28.6%) were male, with a mean age (SD) of 63 (10.9) years. Malignancies included: metastatic melanoma (n=4), metastatic squamous cell carcinoma (n=1), breast cancer Stage IIA/IIB (n=1), and metastatic endometrial adenocarcinoma (n=1). ICIs used included: pembrolizumab (n=2), nivolumab (n=1), cemiplimab (n=1), and ipilimumab/nivolumab combination followed by nivolumab monotherapy (n=2), which were discontinued due to SSc symptoms within 1-13 months of initiation. Serologies showed ANA positivity in 4 patients (57.1%), with SSc-specific antibodies (anti-Scl-70) detected in 1 patient. Other antibodies detected included anti-RP-11, anti-RP-155, anti-Ro-52, anti-chromatin, and anti-OJ. 2 patients had negative serologies, 1 with elevated inflammatory markers. All patients had scleordactyl (diffuse 57.1%, limited 42.9%) and extra-cutaneous features, most commonly Raynaud’s phenomenon (71.4%). Other manifestations included inflammatory arthritis (42.9%), nailfold capillary changes (42.9%), esophageal dysmotility (28.6%), telangiectasia (14.3%), and sicca symptoms (14.3%). No patients developed interstitial lung disease, pulmonary arterial hypertension, or scleroderma renal crisis. Management included ICI cessation for all patients, prednisone (85.7%), disease-modifying antirheumatic drugs (mycophenolate mofetil 57.1%, methotrexate 28.6%, hydroxychloroquine 28.6%), infliximab and intravenous immunoglobulins, and vasodilatory therapies. All malignancies were stable at 6 months post-ICI therapy. Conclusion ICI-SSc is a significant irAE primarily characterized by cutaneous manifestations but, in contrast to previous reports, this case series demonstrates that extra-cutaneous manifestations and seropositivity can occur. Along with ICI-cessation, immunosuppressive therapy was effective in symptom control without compromising cancer stability. This work may assist those involved in caring of patients with ICI-SSc to initiate immunosuppressive therapy and minimize the risk of end-organ complications. References [1.] Cho LK. Rheum Dis Clin North Am 2024;50:301-12.
2026-06-23 | Fibroblast Mitochondrial Ca2+ Overload Drives Skin Fibrosis via mtDNA Leakage and cGAS-STING Activation in Systemic Sclerosis.
To explore the clinical relevance of mitochondrial DNA (mtDNA) in systemic sclerosis (SSc) and elucidate the mechanism by which mtDNA leakage drives fibroblast activation. Plasma mtDNA was quantified by qPCR in 50 patients with SSc and 20 healthy controls (HC). Primary dermal fibroblasts from 5 diffuse cutaneous SSc (dcSSc) and 5 HC (n= 5 per group) were analyzed for mitochondrial structure, function and RNA-seq profiling. The opening of mitochondrial permeability transition pore (mPTP) and oligomerization of VDAC1 were examined with Ca2+ modulators and inhibitors. STING knockdown (siRNA) was performed for validation. The STING inhibitor H-151 was evaluated in vitro and in a bleomycin-induced skin fibrosis model (n= 6 mice per group). Plasma mtDNA levels were significanly higher in SSc than in HC, negatively correlating with forced vital capacity (FVC)% (r = -0.436, P < 0.01) , and correlating with modified Rodnan skin score (mRSS) ( r = 0.807, P < 0.001 ), IL-6 ( r = 0.667, P < 0.001 ) and TGF-β ( r = 0.678, P < 0.001 ). SSc fibroblasts exhibited abnormal mitochondrial morphology and dysfunction. Increased MCU and VDAC1 promoted mitochondrial Ca2+ overload, mPTP opening, VDAC1 oligomerization, cytosolic mtDNA accumulation, which activated the cGAS-STING pathway and triggered profibrotic responses. Pharmacologic blockade of mPTP or VDAC1 reduced cytosolic mtDNA, while H-151 suppressed profibrotic markers in SSc fibroblasts and attenuated dermal thickening and collagen deposition in bleomycin-treated mice. The Ca2+-mtDNA-cGAS/STING axis drives fibroblast activation and skin fibrosis in SSc, representing a promising therapeutic target.
cell therapies
2026-09-14 | Mesenchymal Stem Cell Therapy for Systemic Sclerosis: Current Evidence and Clinical Applications.
Systemic sclerosis is a multisystem autoimmune disease characterized by immune dysfunction, vasculopathy, and progressive fibrosis, yet current therapies rarely address these pathogenic axes simultaneously. Mesenchymal stem cell therapy has gained increasing interest as a disease-modifying strategy because its therapeutic activity appears to depend largely on paracrine signaling rather than durable engraftment. Through these mechanisms, mesenchymal stem cells may suppress profibrotic fibroblast activation, recalibrate innate and adaptive immune responses, and enhance vascular repair. Cell-free approaches, particularly extracellular vesicles and exosome-based therapeutics, are further expanding the translational potential of this field by offering scalable alternatives to live cell administration. Early clinical studies of systemic infusion and local delivery for complications such as hand dysfunction (reduced grip strength, joint contracture, and impaired fine motor function) and digital vasculopathy have demonstrated feasibility, acceptable short-term safety, and encouraging signals in skin and vascular outcomes. Nevertheless, long term clinical benefit remains uncertain because published studies are few and heterogeneous in cell source, manufacturing and expansion protocols, dose, route, concomitant therapy, and endpoint selection. Progress in this area will require standardized potency frameworks, improved control of senescence and functional drift, phenotype-specific trial stratification, and harmonized outcome hierarchies across vascular and cutaneous domains. Integration of immune and vascular biomarkers as pharmacodynamic readouts, together with multicenter randomized controlled trials and long-term follow-up, will be essential for defining efficacy and advancing targeted cell-free therapeutic platforms in systemic sclerosis.
2026-08-01 | Isolated Neck Extensor Myositis and Chest Wall Skin Thickening: Case Report of a Rare Initial Presentation of Systemic Sclerosis and Overlap Myositis
Background Systemic sclerosis is a multisystemic connective tissue characterized by immune dysregulation, fibrosis and vasculopathy. Skin thickening, a cardinal feature of this disease process, characteristically progresses in a centripetal pattern.[1] Overlap disease with idiopathic inflammatory myositis can be seen, classically involving weakness of the proximal muscle groups of the upper and lower limbs.[2] Case Report We report the case of a 46-year-old female referred for assessment of possible systemic sclerosis with a several month history of neck extensor weakness, Raynaud’s phenomenon, moderate skin thickening isolated to the chest, positive ANA 1:640 nucleolar, and elevated CK of 436. Over the next few months, she developed rapidly progressive and severe skin thickening of the proximal and distal extremities, face and hands with associated sclerodactyly. Advanced serological testing was negative for myositis or systemic sclerosis associated with autoantibodies. Baseline investigations including echocardiogram, pulmonary function test and high-resolution CT scan of the lungs were normal. MRI of the extremities and neck demonstrated mild edema to the posterior neck paraspinal muscles, EMG of the neck extensors was positive for irritable myopathy, and subsequent muscle biopsy of the cervical paraspinal muscles demonstrated marked fibrosis with end-stage muscle atrophy in keeping with partially treated myositis. Punch biopsies of the skin demonstrated sclerosing dermatitis. A diagnosis of diffuse cutaneous systemic sclerosis with overlap myositis was made. She was treated initially with methotrexate followed by mycophenolate, however due to rapidly progressive cutaneous disease she underwent autologous hematopoietic stem cell transplant approximately 8 months after initial presentation. With ongoing follow-up 6 months post-transplant, the patients’ skin thickening had significantly improved, her myositis and Raynaud’s phenomenon had resolved, and she remained in remission off all immunosuppressive therapies. Conclusion Isolated neck extensor myositis and initial skin thickening of the chest is a rare presentation of early diffuse cutaneous systemic sclerosis. This case highlights the importance of close follow up of patients with atypical disease manifestations and seeking histopathological correlation to assist in making a definitive diagnosis. References [1.] Volkmann E. Lancet 2022;401:304-18. [2.] Bhansing K. Arthritis Res Ther 2014;16:R111.
2026-06-27 | High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.
Purpose: The 2023 EULAR update recommends autologous hematopoietic stem-cell transplantation preceded by high-intensity immunosuppression (HI-IS/HSCT) for selected poor-prognosis early diffuse cutaneous systemic sclerosis (dcSSc). As real-world data remain scarce, we compared 5-year outcomes of HI-IS/HSCT recipients with propensity-matched controls receiving standard care. Because undergoing HI-IS/HSCT identifies poor-prognosis systemic sclerosis (SSc), we compared their 5-year outcomes with those of propensity-matched dcSSc controls receiving standard care. This retrospective multicenter study analyzed ACR/EULAR-2013 dcSSc patients treated after 2013 from the Greater Paris University Hospitals and French national registry. Patients had poor-prognosis SSc defined by early disease and rapid skin progression or organ involvement. HI-IS/HSCT recipients were matched 1:1 with conventional immunosuppression controls using nearest-neighbor 20-variable propensity scores (covering demographics, antibodies, organ involvement, and prior treatments). Outcomes included overall survival (OS), event-free survival (EFS), progression-free survival (PFS), and toxicities at 60 months. Exploratory multivariable logistic regression identified predictors of EFS. We analyzed 100 patients, equally divided between the HI-IS/HSCT and control groups. Five-year OS was similar (90%) in both groups. However, HI-IS/HSCT was associated with significantly improved 5-year event-free survival (76% vs 46%, p = 0.021) and progression-free survival (82% vs 40%, p = 0.001), a more favorable Global Rank Composite Score (p = 0.001), greater skin improvement (p < 0.001), and stabilization of FVC (p = 0.034) compared with controls. Prior DMARD burden was significantly lower in the transplant group (median 1 vs 2, p < 0.0001). Conditioning containing fludarabine/rituximab showed a non-significant trend towards higher EFS compared to CYC + ATG alone (82.6% vs 66.7%, p = 0.33). HI-IS/HSCT caused higher grade ≥4 toxicities (36% vs 8%, p < 0.001), with a 2% procedure-related mortality. Older age and pre-existing cardiac involvement were independently associated with worse EFS after transplant. In patients with poor-prognosis dcSSc, 5-year overall survival was high and similar between HI-IS/HSCT and modern conventional care. However, HI-IS/HSCT provided significantly superior event-free and progression-free survival, skin improvement, and pulmonary stabilization. These findings support early HSCT as a highly effective disease-stabilizing therapy in carefully selected patients, provided they undergo rigorous cardiac screening.
2026-06-01 | OC.56 Safety and early efficacy of rapcabtagene autoleucel, an autologous CD19-directed chimeric antigen receptor T-cell therapy, in severe refractory diffuse cutaneous systemic sclerosis
Introduction
Diffuse cutaneous systemic sclerosis (dcSSc) can be severe, with potential significant organ involvement, leading to end-organ failure and death. Therapeutic options for dcSSc are limited and inadequately address clinical manifestations or modify disease progression. CD19-targeted chimeric antigen receptor (CAR)-T cell therapy shows promise, with the potential to induce deep and sustained B cell depletion, thereby facilitating an immune system reset and offering the prospect of long-term remission in autoimmune diseases, including dcSSc.
Material and Methods
This Phase 2 open-label, AUTOGRAPH study (CYTB323K12201) evaluates rapcabtagene autoleucel, an autologous CD19-directed CAR-T cell therapy, in participants with severe, refractory (inadequate response to >2 prior systemic therapies) dcSSc. The study consists of two sequential cohorts: Cohort 1, a single-arm safety cohort, followed by a randomized and controlled Cohort 2. All participants in Cohort 1 underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by a single intravenous infusion of rapcabtagene autoleucel, with the initial three dosed sequentially with a 28-day observation period between participants; subsequent participants were dosed in parallel. All participants were hospitalized >=14 days post-infusion.
Results
Cohort 1 included 5 females and 1 male, with median: age of 49 years (range: 32–56), disease duration of 22 months (range: 10–35) and modified Rodnan skin score (mRSS) of 36.5 (range: 34–48); 5/6 participants were anti-Scl-70 positive and, 1/6 were anti-RNA polymerase 3 positive. All participants had progressive skin disease; two with concurrent progressive interstitial lung disease and one with clinically significant cardiac involvement. Participants treated with rapcabtagene autoleucel in Cohort 1 demonstrated rapid and profound B cell depletion following CAR-T expansion. Two participants with >=20 weeks of follow-up demonstrated a >=30% reduction in the mRSS along with stabilization or improvement in pulmonary function and were able to discontinue immunosuppressive therapies. Rapid improvements were noted in patient and physician global assessment and disability index. In all 3 participants with >=4 months of follow-up, circulating CD19 B cells reappeared 90 days post-infusion. Rapcabtagene autoleucel was well tolerated (table 1). All cases of cytokine release syndrome resolved without sequelae. No instances of immune effector cell-associated neurotoxicity syndrome were observed. Adverse events were manageable and aligned with the established safety profile of CAR-T cell therapies.
Conclusions
Preliminary data from Cohort 1 suggests a favorable safety profile, CAR-T cell expansion, B cell depletion and promising initial efficacy of rapcabtagene autoleucel in severe refractory dcSSc, supporting its continued evaluation.
Funding Statement
Novartis Pharma AG, Basel, Switzerland.
2026-06-01 | P.249 Efficacy of autologous hematopoietic stem cell transplantation in diffuse cutaneous systemic sclerosis: a case series linking outcomes to patient age and conditioning regimen
Introduction
Diffuse cutaneous systemic sclerosis (dcSSc) is a severe autoimmune disease characterized by progressive skin fibrosis and internal organ involvement. Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a potential therapeutic option for patients with refractory dcSSc following failure of conventional immunosuppressive treatments.
Material and Methods
This case series reports outcomes of three Thai patients with progressive dcSSc (aged 19, 52, and 35 years) who underwent AHSCT after failing standard therapies including methotrexate, mycophenolate mofetil, cyclophosphamide, and rituximab. The conditioning regimen consisted of fludarabine (30 mg/m2), cyclophosphamide (40-60 mg/m2), and anti-thymocyte globulin (2.5 mg/kg). Clinical outcomes were assessed using modified Rodnan skin score (mRSS) and monitoring for transplant-related complications.
Results
All patients achieved neutrophil engraftment within 7-9 days post-transplant. Two patients (aged 19 and 35) demonstrated sustained clinical improvement with dramatic mRSS reductions from 29 to 4 and 20 to 4, respectively. The older patient (aged 52) showed initial improvement (mRSS 32 to 15) but experienced early relapse with progression of myocarditis within two months. Complications included cytomegalovirus reactivation in all cases, Epstein-Barr virus reactivation, drug-induced liver injury, and one case of disseminated Mycobacterium malmoense infection, all successfully managed.
Conclusions
AHSCT can achieve significant clinical improvement in selected patients with refractory dcSSc, particularly younger individuals without severe cardiac involvement. The reduced cyclophosphamide dose (40 mg/m2) may have contributed to early relapse in the older patient, highlighting the importance of individualized conditioning intensity and careful patient selection for optimal outcomes.
antibodies
2026-09-28 | Rituximab in diffuse cutaneous systemic sclerosis: Assessing safety and therapeutic outcomes
Background: Diffuse cutaneous systemic sclerosis (dcSSc) is a severe autoimmune connective tissue disease characterised by progressive skin fibrosis, vasculopathy, and internal organ involvement. Conventional immunosuppressive therapies often provide suboptimal control of skin fibrosis. Rituximab, a B-cell-depleting monoclonal antibody, has emerged as a potential disease-modifying therapy in systemic sclerosis.Aims and Objectives: To evaluate the safety and therapeutic efficacy of rituximab in patients with diffuse cutaneous systemic sclerosis.Materials and Methods: This prospective, single-centre observational study was conducted in the Department of Dermatology, ANMMCH, Gaya. Eleven adult patients with dcSSc and Modified Rodnan Skin Score (MRSS) ≥ 10 were enrolled and treated with Inj. Rituximab 1000mg iv on day 1 and day 14 according to standard therapeutic protocols. Patients were followed monthly for six months. Clinical assessment included MRSS, mouth opening, Raynaud’s phenomenon, dyspnea, dysphagia, Ingram sign, Barnett sign, and salt-and-pepper pigmentation. Statistical analysis was performed using SPSS version 26.0, with significance set at p
2026-08-20 | Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis.
Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7-expressing cytotoxic T cells implicated in diffuse cutaneous SSc. In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months one, three, and six. Flow cytometry quantified CD4+CD319+ and CD8+CD319+ T cells, cytotoxic and activation markers, and stimulated intracellular interleukin-4 (IL-4), IL-17A, and interferon-γ (IFN-γ). Analyses compared abatacept-treated molecular endotypes with placebo and related immune changes to modified Rodnan skin score (mRSS) change. Skin single-cell RNA sequencing included five healthy controls and eight patients with SSc. At baseline, CD319+ T cells showed greater cytokine production, activation, and granzyme and perforin expression than CD319- T cells in 60 evaluable participants (P < 0.001 to P < 0.0001). Abatacept reduced CD4+CD319+ and CD8+CD319+ T cell frequencies at month six; placebo did not. Effects were strongest in patients in the fibroproliferative group, in whom CD8+CD319+ T cells decreased versus placebo (n = 7 versus n = 36; P = 0.0377). In this endotype, abatacept reduced IL-4 in CD4+CD319+ and CD8+CD319+ T cells at month three (P = 0.0468 and P = 0.0287) and IL-17A in CD8+CD319+ T cells at month six (P = 0.0004), whereas IFN-γ was unchanged. Reduction in CD4+CD319+ T cells correlated with mRSS improvement in abatacept-treated patients (r = 0.5297, P = 0.0423). Skin single-cell RNA sequencing showed increased SLAMF7 expression in SSc T cells (P = 0.017), enriched within cytotoxic subsets. CD319+ T cells represent highly differentiated, activated cytotoxic effector populations in SSc. Abatacept selectively modulates these cells and suppresses associated profibrotic and proinflammatory cytokines, particularly in the fibroproliferative subtype, in which CD319+ T cell reductions correlate with clinical improvement.
2026-08-02 | Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey.
To evaluate contemporary global treatment of diffuse cutaneous systemic sclerosis (dcSSc) skin by SSc specialists. An anonymous survey was distributed via the Scleroderma Clinical Trials Consortium, European Scleroderma Trials and Research Group (EUSTAR), and Collaborative National Quality and Efficacy Registry (CONQUER) distribution lists between June and September 2025. The survey comprised four sections: Demographics, Treatment of dcSSc Skin, Impact of Recent Guidelines, and Clinical Trials. Responses included 103 physicians (93 completed): 43% North America, 31% Europe, 15% South America and 12% elsewhere. The majority practice within an SSc centre (80%) and participate in clinical trials (84%). Mycophenolate mofetil (MMF) was preferred first-line treatment (71%) for dcSSc without ILD, rising to 92% for dcSSc with mild/non-progressive ILD. For active skin involvement despite MMF, trial referral was preferred as next step irrespective of ILD (59% without ILD and 58% with ILD). Treatment preferences have evolved, with 40% increasing MMF use and 47% decreasing methotrexate use, over the previous 2-3 years. Biologic use has increased, with 56% and 37% reporting increasing rituximab and tocilizumab use, respectively. For dcSSc without ILD, 85% have prescribed rituximab, and 65% have prescribed tocilizumab. Biologic availability has impacted trial enrolment (73% agreement). Treatment decision-making for dcSSc skin involvement has been materially influenced by recent BSR and/or EULAR guidelines (43% agreement). MMF is preferred first-line for dcSSc. In the absence of compelling scientific justification for combination or step-up immunomodulatory approaches, trial referral is currently the preferred next treatment option. Biologic use is increasing, which impacts trial enrolment.
2026-06-19 | Efficacy of different pharmacological therapies for diffuse cutaneous systemic sclerosis: a systematic review and network meta-analysis.
This study aims to compare the effectiveness of different pharmacological therapies for diffuse cutaneous systemic sclerosis (dcSSc) through a network meta-analysis (NMA). Randomized controlled trials (RCTs) on pharmacological interventions for dcSSc were systematically searched in PubMed, Embase, Cochrane Library, and Web of Science up to 2026. A Bayesian network meta-analysis was carried out using Markov Chain Monte Carlo (MCMC) methods via R software and its GeMtc package. Outcomes assessed included Modified Rodnan Skin Score (MRSS), pulmonary functions (forced vital capacity [FVC], and diffusing capacity of the lung for carbon monoxide [DLCO]), and Health Assessment Questionnaire (HAQ). Effect sizes were reported as standardized mean differences (SMDs) with corresponding 95% credible intervals (95% CrIs). A total of 20 RCTs involving 1,760 patients and 16 interventions were included. The results revealed that rituximab was the most effective intervention for reducing MRSS (SMD = - 3.4, 95% CrI (- 4.2, - 2.7)), followed by cyclophosphamide (CTX) (SMD = - 2.8, (- 3.3, - 2.2)), and belimumab (SMD = - 1.5, (- 2.5, - 0.39)). Belimumab (SMD = 1.9, (0.75, 3.1)) and CTX (SMD = 1.3, (0.86, 1.8)) topped FVC improvement. Methotrexate (MTX) was the most effective for enhancing DLCO (SMD = 0.52, (0.046, 0.99)). Belimumab (HAQ: SMD = - 3.8, (- 5.5, - 2.1)) and CTX (HAQ: SMD = - 2.9, (- 3.4, - 2.3)) were significantly effective in lowering HAQ scores. B-cell-targeted therapies (e.g., rituximab and belimumab) seemed to outperform other therapeutic agents in lowering MRSS and HAQ scores. Conventional immunosuppressants (e.g., CTX and MTX) might be more effective in enhancing pulmonary functions. Treatment strategies should be tailored according to the extent and severity of organ involvement.
2026-06-10 | Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.
Tocilizumab (TCZ) has shown beneficial effects on interstitial lung disease (ILD) in systemic sclerosis (SSc). We aimed to assess the real-life safety and effectiveness of TCZ on several SSc-related domains using data from a French-Italian multicentre cohort. We conducted a retrospective analysis of patients with SSc treated with TCZ across 15 referral centres. The following clinical data were collected at 12 months before TCZ initiation, at baseline and at 12 and 24 months of treatment: modified Rodnan skin score (mRSS), pulmonary function tests, Disease Activity Score in 28 joints using C reactive protein, digital ulcers and cardiac biomarkers. ILD progression was defined as a decline ≥5 in %predicted forced vital capacity (%pFVC) over 12±3 months. 197 patients were included (88% female; median age 57 years; median disease duration 9 years); 67% were antitopoisomerase I positive. TCZ monotherapy was used in 29% of cases, methotrexate was the most frequent combined treatment (35%). In SSc-associated ILD, %pFVC declined significantly from -12 months to baseline (81% to 77%; p=0.003). On TCZ introduction, %pFVC stabilised and the proportion of progressors declined from 43% to 24% (p=0.015). Among diffuse cutaneous patients, mRSS decreased significantly at 12 and 24 months. Digital ulcers, arthritis activity and cardiac biomarkers also improved. Infections were the most frequent adverse events (22.8%). TCZ was discontinued in 32% of patients, mainly for inefficacy. Pulmonary arterial hypertension and older age predicted TCZ failure, whereas elevated CRP predicted better response. In this large real-life cohort, TCZ was safe and associated with consistent benefits across different domains, supporting its role as a potential disease-modifying treatment in selected patients with SSc.
other
2026-06-10 | High mobility group motif proteins' role in fibrosis, inflammation, and vascular injury in systemic sclerosis.
Systemic Sclerosis (SSc) is an idiopathic systemic autoimmune disease characterized by progressive cutaneous and systemic fibrosis, severe vasculopathy, and multiple humoral and cellular immunological alterations. The pathogenesis of SSc is highly complex and remains incompletely elucidated. The fibrotic process is a crucial component of SSc and is responsible for organ failure and high mortality. Although an increasing understanding of the fibrotic process has enabled the clinical development of antifibrotic therapeutic agents, these agents have limited clinical efficacy. Recently, the potential role of a group of transcription factors containing a High Mobility Group (HMG) motif, in the development and pathological manifestations of SSc has been postulated. HMG proteins (notably HMGB1 and SOX9) act as profibrotic and proinflammatory transcription factors; however, HMG proteins can also function as damage-associated molecular patterns, amplifying Toll-like receptors and RAGE signaling, promoting endothelial activation, leukocyte recruitment, and stimulating the production of profibrotic cytokines. This convergent role of HMG proteins across various aspects of SSc pathogenesis, including immune dysregulation, vasculopathy, and fibrosis, makes them among the most attractive novel regulators and a desirable therapeutic target for SSc. Here, we review the recent evidence on the role of HMG proteins in SSc pathogenesis and explore the potential role of inhibiting their function.
2025-09-08 | Overlapping Connective Tissue Disease-Polymyositis and Diffuse Systemic Scleroderma: A Case Report.
Polymyositis with concomitant scleroderma is a rare, progressive condition with profound consequences if not addressed promptly. Severity and symptom presentation varies between patients, and much is unknown about how best to treat overlapping connective tissue diseases. This case discusses the rare presentation, medical evaluation, and successful treatment of a 46-year-old woman with excessive muscle atrophy, weakness, and tissue fibrosis, who was diagnosed with overlapping connective tissue disorder after extensive work up that included a muscle biopsy, skin punch biopsy, and autoantibody lab work. This patient recovered well with the use of mycophenolate mofetil demonstrating promising results for similar patients and offering insight into potential methods of evaluation and medical management. Studying cases like this one give providers more knowledge about overlapping connective tissue disease and how to best diagnose and manage them.
2025-06-26 | Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis.
Background/Objectives: Systemic sclerosis (SSc) is a progressive autoimmune disease characterized by widespread fibrosis, including skin thickening. Mycophenolate mofetil (MMF) is commonly used in SSc-associated interstitial lung disease, but its efficacy in improving skin fibrosis has not been systematically evaluated. This study aimed to assess the therapeutic effect of MMF on cutaneous sclerosis in SSc, as measured by the modified Rodnan skin score (mRSS). Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. PubMed, Embase, and Web of Science were searched from January 2000 to March 2025. Studies reporting mRSS outcomes in SSc patients treated with MMF were included, provided that the effect of MMF could be separately evaluated when used alongside other therapies. Risk of bias was assessed using the Cochrane RoB 2.0 tool for randomized controlled trials and the ROBINS-I tool for non-randomized studies. A random-effects model was used to estimate the pooled mean change in mRSS. Heterogeneity and publication bias were evaluated. Results: Eight studies involving 569 patients were included. The pooled mean reduction in mRSS following MMF treatment was -5.82 (95% CI: -7.46 to -4.19), exceeding the minimal clinically important difference. Heterogeneity across studies was substantial (I2 = 82.6%). A post hoc exploratory subgroup analysis suggested greater improvement in early disease (<2 years), though this finding requires confirmation in prospective studies. MMF was generally well tolerated, with low discontinuation rates due to adverse events. Conclusions: MMF is associated with a statistically and clinically significant improvement in skin fibrosis in patients with SSc. These findings support its use as a frontline therapy for progressive cutaneous involvement, although further prospective studies are needed to identify optimal candidates for treatment.
2025-05-12 | Full Recovery Over One Year of the Overlap Syndrome Scleromyositis to Maintenance Therapy with Mycophenolate Mofetil and Rituximab, which Relapsed within 8 Months of Discontinuation.
Scleromyositis (SM) is an emerging, distinct entity within the spectrum of diffuse systemic sclerosis (SSc) and autoimmune inflammatory myopathies. It can carry a poorer prognosis due to multisystem involvement and extramuscular complications, with no consensus on treatment strategies currently available. We report on a 20-year-old woman with a history of recurrent infections over the past year, who presented with persistent myalgias for four months. On examination, she exhibited muscle weakness in the scapular and pelvic girdles, along with sclerodactyly. Laboratory results showed elevated creatine kinase (13,000 U/l), aldolase (15.6 U/l), lactate dehydrogenase (1,481 U/l) and myoglobin (4,400 ng/ml). Autoimmune screening was positive for antinuclear antibodies, anti-PM-scleroderma (anti-PM-Scl) 75 and 100, and anti-CENP-B antibodies. An MRI of the pelvic girdle indicated acute/subacute myositis, and electromyography revealed both distal and proximal myopathy. Muscle biopsy showed extensive necrosis with minimal inflammatory infiltration. Nailfold capillaroscopy demonstrated an early scleroderma pattern, while CT and spirometry revealed mild interstitial restrictive lung disease. Initial treatment involved intravenous immunoglobulin (IVIG), mycophenolate mofetil (MMF) and prednisolone. This was followed by maintenance therapy with MMF and rituximab (RTX) every six months for the first year. Over six months, the patient showed progressive improvement in muscle strength and normalisation of muscle enzyme levels. In conclusion, SM presents with variable phenotypes, ranging from mild to extensive systemic involvement. This case underscores the importance of individualised patient stratification and highlights the need for structured induction and maintenance therapy due to the disease's extensive activity. Scleromyositis (SM) is a rare and poorly understood condition that combines features of systemic sclerosis and immune-mediated myositis, often linked to anti-PM-scleroderma antibodies.Despite efforts to classify SM, it demonstrates unique clinical patterns that distinguish it from other myositis subtypes.The management of SM remains challenging, as there are no established guidelines or standardised treatment protocols.
2023-06-20 | Regulation of MicroRNA Expression in Scleroderma and Idiopathic Pulmonary Fibrosis: A Research Study
Introduction: Scleroderma (SSc) is an autoimmune disorder with the hallmark of fibrosis of the skin, vasculature and internal organs. Patients with SSc and undifferentiated connective tissue disease (UCTD) are susceptible to interstitial lung disease (ILD), leading to decreased lung function and death. Idiopathic pulmonary fibrosis (IPF) is a form of ILD that is not associated with extrapulmonary manifestations. In this study, lung involvement of SSc was studied by observing how disease progression and pathogenesis differ among patients with SSc, UCTD, and ILD compared to healthy controls and patients with IPF. Our group has previously identified disease targets through microRNA sequencing, including the DICER enzyme, which works closely with the protein DGCR8 and the enzyme DROSHA in the RNA interference pathway. The canonical pathway stipulates that DICER processes microRNAs in the cytosol while DGCR8 and DROSHA process microRNAs in the nucleus. DICER, DROSHA, and DGCR8 are hypothesized to contribute to ILD progression. Methods: Human peripheral blood mononuclear cells (PBMCs) were isolated from voluntary participants, including healthy controls. PBMCs were subsequently lysed with subcellular fractionation buffer. Western blotting was done on the resulting cytosolic and nucleic fractions for DICER, DROSHA, and DGCR8 protein expression. The cytosolic fractions were normalized to GAPDH, while the nucleic fractions were normalized to B2M. Nonparametric Kruskal‐Wallis tests were used for statistical analysis. Results: The medians were significantly higher for healthy controls for DICER in the nucleus with a p-value of 0.0302, and DROSHA in the cytosol with a p-value of 0.0406 compared to patients with SSc, UCTD, and IPF. Discussion: Differences in expression were found for DROSHA in the cytosol and DICER in the nucleus, suggesting dysregulation of the non-canonical RNA interference pathways in SSc, UCTD, and IPF patients. Variability of disease progression within the groups could lead to variable enzyme and protein levels within the same disease status. With larger sample sizes, statistically insignificant differences would become significant. Lipid nanoparticle technology could be used to deliver deficient microRNAs to silence mRNA in patients. Conclusion: Due to dysregulation of the RNA interference pathway, microRNAs may be inadequately processed in the patient groups.
proteins
2026-08-07 | Pyruvate kinase M2 is elevated in systemic sclerosis and plays a role in its pathogenesis.
Systemic sclerosis is an autoimmune fibrotic skin disease characterised by immune activation and fibrosis. Fibroblasts are at the core of this fibrotic process, differentiating into effector myofibroblasts; however, the drivers of this process remain obscure. Recently, metabolic changes in cells in fibrotic diseases have been uncovered, with changes in the TCA cycle and glycolysis being observed. The objective of this work was to elucidate the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in systemic sclerosis. Serum from early diffuse systemic sclerosis (SSc) patients and healthy controls (HC) was collected for PKM2 analysis by ELISA. Fibroblasts were isolated from HC and SSc biopsies and treated with transforming growth factor-beta 1 (TGF-β1) to assess PKM2 expression. PKM2 was pharmacologically modulated, and collagen and Extracellular Matrix (ECM) regulators were evaluated. Metabolic activity was assessed using Seahorse assays, and lactate transport was chemically inhibited. Chromatin immunoprecipitation was performed using a histone lactylation-specific or isotype antibody, and lactate or acetate supplementation experiments were conducted. We found significantly elevated circulating and fibroblast PKM2 in SSc patients. Fibroblast PKM2 could be induced in healthy fibroblasts by TGF-β1 exposure. Furthermore, PKM2 drives a metabolic shift to glycolysis that can be blocked by forced tetramerisation of PKM2 from its dimeric form; this resulted in reduced ECM and matrix regulators. Mechanistically, PKM2-mediated glycolysis results in elevated lactate, which drives collagen via epigenetic regulation by histone H3K18 lactylation. Blockade of PKM2 dimerisation reduced Histone H3 at Lysine 18 (H3K18) lactylation at the collagen promoter, which could be restored with lactate but not acetate. We further demonstrated that lactate-induced collagen is partially mediated by HIF-1α. PKM2 drives activation of fibroblasts in SSc via metabolic changes such as glycolysis. Taking advantage of PKM2 tetramerisation or blockade of lactate generation could be a possible therapeutic option in a disease with few treatment options.
2026-02-11 | Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis.
The study elucidates the impact of the programmed cell death protein 1 (PD-1) pathway on immune activation and fibrosis in diffuse cutaneous systemic sclerosis (dcSSc). We obtained blood and skin biopsies from patients with dcSSc and healthy controls (HCs). Soluble PD-1 was measured in serum. Human recombinant PD-1 protein (PD-1:Fc) and anti-PD-1 antibodies were used to stimulate peripheral blood mononuclear cells (PBMCs), HC, and systemic sclerosis (SSc) dermal fibroblast cultures, and cocultures. PD-1-positive (PD-1pos) and PD-1-negative (PD-1neg) populations of dcSSc PBMCs were characterised. We used a murine bleomycin model of pulmonary injury to study the effect of PD-1:Fc on pulmonary fibrosis in vivo. Soluble and cellular PD-1 were elevated in dcSSc compared to HC. Naïve fibroblasts differed between HC and dcSSc, but did not respond to PD-1:Fc treatment. Transforming growth factor β (TGF-β)-stimulated fibroblasts from dcSSc displayed a myofibroblast profile with a differential clustering compared to HC fibroblasts. PD-1:Fc downregulated the secretion of extracellular matrix (ECM) proteins, surface markers of fibroblast activation, and the production of inflammatory cytokines in TGF-β-stimulated in vitro cultures. PD-1pos SSc T cells had a different and more regulatory transcriptional profile than the PD-1neg T cell population. In vivo studies demonstrated that treatment with PD-1:Fc inhibited the development of lung fibrosis and the production of profibrotic cytokines. Administrating PD-1:Fc attenuated inflammation and ECM protein production in dcSSc in vitro models and decreased systemic inflammation and pulmonary fibrosis in the bleomycin-induced fibrosis model in mice. Our data indicate that modulating the PD-1/PD-Ligand 1 axis represents a novel therapeutic avenue in dcSSc.
2025-04-01 | P130 Prolonged treatment with novel cyclical RP peptides reprogrammes M2 macrophages towards a resolving phenotype in diffuse cutaneous systemic sclerosis
Abstract Background/Aims Alternatively activated (M2) macrophages are believed to promote pathological fibrosis and represent a potential therapeutic target in fibrotic diseases including systemic sclerosis (SSc). Novel 10 amino acid therapeutic peptides targeting M2 macrophages, via binding to the CD206 receptor, represent promising therapeutics by reducing macrophage-stimulated fibrosis in tissue culture and mouse model systems. In this study, we investigate the potential for prolonged treatment with novel cyclical variants of the RP peptides to reprogramme pathogenic SSc macrophages to a pro-resolving phenotype. Methods Macrophages were derived from peripheral blood monocytes in the presence of M-CSF (4ng/ml) for 7 days from patients with diffuse cutaneous SSc (dcSSc) and healthy controls (n=3 dcSSc and 1 HC). On day 7, 9 and 11, macrophages were treated with 10µM of RP peptide (cyclical RP606-30, or comparator RP; RP class) or left untreated in n=6 replicates per treatment group. On day 14, media were removed and cells were collected, washed, lysed for RNA extraction, and profiled by qPCR for CD206 (pro-fibrotic M2-macrophage marker), CD86 (pro-inflammatory M1-macrophage marker) and MERTK (pro-resolution regulatory efferocytosis marker), relative to the reference gene TBP. The ratios of CD86/CD206 were used to assay pro-inflammatory vs. pro-fibrotic and MERTK/CD206 for pro-resolution vs. pro-fibrotic phenotypes. Results For individual patients with dcSSc, cyclical RP606-30, but not comparator RP, reduced CD206 expression (Patient 1: 5.74 vs. 4.10, p=NS; Patient 2: 7.38 vs. 3.92, p = 0.014; Patient 3: 2.17 vs. 0.26, p = 0.021, relative expression level untreated vs. RP606-30) and enhanced the ratio of MERTK/CD206 (Patient 1: 0.22 vs. 0.35, p=NS; Patient 2: 0.18 vs. 0.31, p = 0.0007, relative expression untreated vs. RP606-30). Similar effects were seen in healthy control macrophages treated with RP606-30, with a significant decrease in relative CD206 expression (p = 0.012), and increase in both the MERTK/CD206 (p < 0.0001) and CD86/CD206 (p < 0.0001) ratios. Combining data for dcSSc macrophages indicated that CD206 expression was reduced with RP606-30 treatment compared to no treatment (mean ± SEM: 2.76 ± 0.51 vs. 5.06 ± 0.73, p = 0.079), and MERTK expression was slightly increased (1.24 ± 0.07 vs. 1.13 ± 0.17, p = 0.809). Compared to untreated cells, RP606-30 treatment significantly increased both the CD86/CD206 (M1/M2) ratio (2.04 ± 0.34 vs. 0.86 ± 0.22, p = 0.0036) and MERTK/CD206 ratio (0.33 ± 0.03 vs. 0.20 ± 0.03, p = 0.016). Conclusion We found that prolonged treatment with RP606-30, a cyclical RP peptide, reduced relative CD206 expression, and significantly increased the CD86/CD206 (M1/M2) ratio and the MERTK/CD206 ratio in macrophages derived from patients with dcSSc. These findings indicate that RP peptides reprogramme macrophages from a pro-fibrotic towards a pro-resolution phenotype. To further characterise the phenotypic changes involved in the polarisation of macrophages towards this pro-resolving phenotype, we plan to assay the media for levels of pro-resolving lipid metabolites (LXA4 and RvD1). Disclosure J. Mendall: None. B. Ahmed Abdi: None. K. Shetty: None. S. Lopez Garces: None. V. Ong: None. C. Denton: None. D. Abraham: None. C. Yates: Corporate appointments; Scientific Officer Riptide. J. Jaynes: Corporate appointments; Scientific Officer Riptide. H. Lopez: Corporate appointments; CEO of Murigenics. G. Martin: Corporate appointments; Senior Scientific Officer Riptide. R.J. Stratton: None.
2024-07-26 | The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis.
Systemic sclerosis (SSc) is an autoimmune connective tissue disease with a triad of features that include vascular abnormalities, inflammation and skin and lung fibrosis. At the core of the disease is the activation of myofibroblasts from quiescent fibroblasts and this can be modified by various cytokines. IL-41 is a recently described cytokine that was initially characterised as an adipokine as it was highly expressed in adipocytes and adipose tissue. However, it has recently been identified as being widely expressed and has immunomodulatory functions. This study examined the circulating levels of IL-41 and its expression in skin biopsies. We demonstrated significantly reduced levels of IL-41 in diffuse SSc that was also mirrored in the skin of SSc patients. AMPK has been proposed as a downstream target of IL-41, so we also measure mammalian target of rapamycin in skin and found that this is elevated in SSc patients. We speculate that IL-41 maybe an antifibrotic cytokine and its reduction may facilitate the activation of fibroblasts.
2024-06-01 | Interferon-γ Induces Interleukin-6 Production and Alpha-smooth Muscle Actin Expression in Systemic Sclerosis Fibroblasts.
Systemic sclerosis (SSc) is an autoimmune systemic disease that is characterized by immune dysregulation, inflammation, vasculopathy, and fibrosis. Tissue fibrosis plays an important role in SSc and can affect several organs such as the dermis, lungs, and heart. Dysregulation of interferon (IFN) signaling contributes to the SSc pathogenesis and interferon regulatory factor 1 (IRF1) has been indicated as the main regulator of type I IFN. This study aimed to clarify the effect of IFN-gamma (-γ) and dexamethasone (DEX) on the IRF1, extracellular signal-regulated kinase 1/2 (ERK1/2), and the expression of alpha-smooth muscle actin (α-SMA) in myofibroblasts and genes involved in the inflammation and fibrosis processes in early diffuse cutaneous systemic sclerosis (dcSSc). A total of 10 early dcSSc patients (diffuse cutaneous form) and 10 unaffected control dermis biopsies were obtained to determine IFNγ and DEX effects on inflammation and fibrosis. Fibroblasts were treated with IFNγ and DEX at optimum time and dose. The expression level of genes and proteins involved in the fibrosis and inflammation processes have been quantified by quantitative real-time PCR (RT-qPCR) and western blot, respectively. IFNγ could up-regulate some of the inflammation-related genes (Interleukin-6; IL6) and down-regulate some of the fibrosis-related genes (COL1A1) in cultured fibroblasts of patients with early dcSSc compared to the untreated group. Besides, it has been revealed that IFNγ can induce fibroblast differentiation to the myofibroblast that expresses α-SMA. Concerning the inhibitory effect of IFNγ on some fibrotic genes and its positive effect on the inflammatory genes and myofibroblast differentiation, it seems that IFNγ may play a dual role in SSc.
small molecules
2026-09-04 | Methotrexate Versus Mycophenolate Mofetil as First-Line Therapy in Systemic Sclerosis: Evidence from Clinical Trials and Real-World Studies—A Narrative Review
Systemic sclerosis (SSc) is a heterogeneous autoimmune connective tissue disease characterized by immune activation, vasculopathy and progressive fibrosis of the skin and internal organs. Immunosuppressive treatment is commonly used in early inflammatory disease and in SSc-associated interstitial lung disease (SSc-ILD), yet the optimal first-line agent depends on the dominant clinical phenotype. Methotrexate (MTX) and mycophenolate mofetil (MMF) are two widely used conventional immunomodulatory options. This review summarizes the clinical trial evidence from the last four decades and places it into the context of contemporary guideline recommendations and real-world comparative effectiveness data. Two randomized placebo-controlled trials support a modest role for MTX in early diffuse cutaneous SSc, particularly for skin and musculoskeletal manifestations, but evidence for lung benefit is limited. MMF has stronger evidence for SSc-ILD, principally from the Scleroderma Lung Study II, a randomized double-blind trial showing comparable efficacy to oral cyclophosphamide with better tolerability, and from subsequent pilot, open-label, and real-world studies. Overall, the current evidence supports a phenotype-driven approach: MTX may be considered when skin or joint disease predominates without clinically relevant ILD, whereas MMF is generally preferred for SSc-ILD and systemic inflammatory disease. Direct head-to-head MTX versus MMF trials are lacking and remain an important research priority.
2026-09-03 | A compact five-gene immuno-fibrotic profile distinguishing systemic sclerosis subtypes with PXDN validated as a fibrosis-associated target.
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterized by a paucity of reliable biomarkers for accurate diagnosis and subtype stratification. The considerable clinical variability between diffuse and limited cutaneous subtypes underscores an urgent need for molecular tools that can dissect this heterogeneity and guide therapeutic strategies. To address this, we employed a multi-step computational approach. Initially, Weighted Gene Co-expression Network Analysis (WGCNA) was applied to the GSE130955 dataset to identify disease-associated modules. This was followed by the application of three machine-learning algorithms-LASSO regression, random forest, and SVM-RFE-to the GSE181549 dataset for hub gene selection. Immune cell infiltration was estimated using CIBERSORT, and the expression of candidate genes was validated at single-cell resolution using the GSE138669 dataset. Experimental validation was performed for the top candidate, PXDN, assessing its protein expression in human fibroblasts, SSc patient skin, and a bleomycin-induced murine fibrosis model. Finally, molecular docking with AutoDock Vina was conducted to evaluate the binding affinity of small molecules to PXDN. WGCNA identified a module strongly correlated with SSc status (r = 0.73, p < 2e-16), which was enriched in immune chemotaxis and extracellular matrix organization pathways. The convergence of the three machine-learning algorithms nominated a five-gene signature (CPXM1, ELN, GSTM5, PXDN, PDE7B), which demonstrated high diagnostic accuracy (AUC = 0.985, 95% CI: 0.965-1) and effectively distinguished diffuse from limited cutaneous SSc. Single-cell analysis confirmed predominant expression of these genes in fibroblast and macrophage populations within SSc lesional skin. Experimentally, PXDN was found to be upregulated by TGF-β1 in human fibroblasts and was significantly elevated in skin and lung tissues from SSc and IPF patients, as well as in the bleomycin-induced mouse model. Although molecular docking nominated Protokylol hydrochloride as a compound satisfying distal-cavity geometric criteria, this serves as a hypothesis-generating finding rather than a confirmed inhibitor. Our integrative analysis identifies a concise immunofibrotic gene signature that robustly distinguishes SSc and its major subtypes. This signature highlights a potential nexus of immune-stromal interactions that may underlie disease heterogeneity, offering candidate biomarkers for molecular stratification and therapeutic targeting. Notably, PXDN emerges as a particularly promising target, warranting further experimental investigation to validate its functional role and therapeutic potential in SSc.
2026-08-26 | Glucocorticoid-Minimizing Triad Therapy (T-D-M) for Early Progressive Diffuse Cutaneous Systemic Sclerosis: An Immunopathological Protocol for Pre-Fibrotic Interception and 12-Month End-Organ Damage Prevention.
Background & Clinical Paradigm Shift: Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by a narrow, critical therapeutic window of opportunity: the early edematous and inflammatory phase spanning months 0 to 15 from the onset of the first non-Raynaud symptom. Standard clinical practice frequently succumbs to therapeutic inertia, initiating intensive disease-modifying therapies only after extensive dermal collagen deposition and fixed visceral fibrosis have taken hold. Furthermore, the administration of moderate-to-high dose glucocorticoids (≥ 15 mg/day) for acute soft tissue inflammation represents the single most potent risk factor for precipitating a catastrophic Scleroderma Renal Crisis (SRC). Clinicians urgently require an objective risk-stratification matrix to predict rapid organ progression and justify aggressive intervention during the reversible, pre-fibrotic stage, utilizing ultra-low-dose glucocorticoid bridging solely to ensure infusion safety. The EPOD-SSc Scoring Matrix: We introduce the Early Progressive Organ Damage in Systemic Sclerosis (EPOD-SSc) matrix, evaluated strictly as a prerequisite within the first 15 months of disease onset. This heuristic matrix scores four high-risk domains: High-Risk Serology (Max +2), Inflammatory Dermal & Musculoskeletal Kinetics (Max +3), Microvascular Angiopathy (Max +2), and Pre-Fibrotic Visceral Inflammatory Markers (Max +2). A cumulative score of ≥ 5 identifies a highly aggressive phenotype, logically and ethically justifying the immediate execution of the Glucocorticoid-Minimizing T-D-M Triad Protocol. Architecture of the T-D-M Protocol: The protocol encompasses three pillars: T - Therapeutic Plasma Exchange (TPE): Days 1–7 (3 sessions) to rapidly clear circulating autoantibodies and profibrotic cytokines. D - Ultra-Slow Rituximab Depletion: Days 10 and 24, administered under an ultra-low-dose steroid safety umbrella (50 mg IV hydrocortisone) to preempt cytokine release syndrome without triggering SRC. M - Mycophenolate Mofetil (MMF) Maintenance: Initiated at Week 4 for sustained long-term lymphocyte suppression. Conclusion: By establishing a definitive 15-month prerequisite window and predicting rapid organ progression, this protocol delineates a clinically actionable, translational pathway to halt disease progression prior to the onset of irreversible structural scarring, safely bridging pathogenic clearance with long-term organ preservation.
2026-08-01 | Systemic Sclerosis Induced by Immune Checkpoint Inhibitors from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO): A Case Series
Objectives Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, improving outcomes in multiple advanced malignancies. Their use is often limited by immune-related adverse events (irAEs), including rare rheumatic irAEs, such as ICI-induced systemic sclerosis (ICI-SSc). Compared to idiopathic SSc, ICI-SSc typically presents with fewer extra-cutaneous manifestations and negative serologies, but data remains limited.[1] This case series describes the clinical presentation, management, and outcomes of patients with ICI-SSc to guide clinicians in balancing autoimmune toxicities with cancer control. Methods A retrospective chart review was conducted on 7 adults diagnosed with systemic sclerosis following ICI exposure between March 2021 and August 2025. All patients were referred to a Canadian academic rheumatology clinic specializing in Immuno-Oncology during ICI therapy. Clinical data was abstracted from medical records, including patient demographics, malignancy type and stage, ICI type and duration, clinical features, serologies, treatment, and outcomes. Results Of the 7 patients identified, 5 (71.4%) were female and 2 (28.6%) were male, with a mean age (SD) of 63 (10.9) years. Malignancies included: metastatic melanoma (n=4), metastatic squamous cell carcinoma (n=1), breast cancer Stage IIA/IIB (n=1), and metastatic endometrial adenocarcinoma (n=1). ICIs used included: pembrolizumab (n=2), nivolumab (n=1), cemiplimab (n=1), and ipilimumab/nivolumab combination followed by nivolumab monotherapy (n=2), which were discontinued due to SSc symptoms within 1-13 months of initiation. Serologies showed ANA positivity in 4 patients (57.1%), with SSc-specific antibodies (anti-Scl-70) detected in 1 patient. Other antibodies detected included anti-RP-11, anti-RP-155, anti-Ro-52, anti-chromatin, and anti-OJ. 2 patients had negative serologies, 1 with elevated inflammatory markers. All patients had scleordactyl (diffuse 57.1%, limited 42.9%) and extra-cutaneous features, most commonly Raynaud’s phenomenon (71.4%). Other manifestations included inflammatory arthritis (42.9%), nailfold capillary changes (42.9%), esophageal dysmotility (28.6%), telangiectasia (14.3%), and sicca symptoms (14.3%). No patients developed interstitial lung disease, pulmonary arterial hypertension, or scleroderma renal crisis. Management included ICI cessation for all patients, prednisone (85.7%), disease-modifying antirheumatic drugs (mycophenolate mofetil 57.1%, methotrexate 28.6%, hydroxychloroquine 28.6%), infliximab and intravenous immunoglobulins, and vasodilatory therapies. All malignancies were stable at 6 months post-ICI therapy. Conclusion ICI-SSc is a significant irAE primarily characterized by cutaneous manifestations but, in contrast to previous reports, this case series demonstrates that extra-cutaneous manifestations and seropositivity can occur. Along with ICI-cessation, immunosuppressive therapy was effective in symptom control without compromising cancer stability. This work may assist those involved in caring of patients with ICI-SSc to initiate immunosuppressive therapy and minimize the risk of end-organ complications. References [1.] Cho LK. Rheum Dis Clin North Am 2024;50:301-12.
2026-06-23 | Fibroblast Mitochondrial Ca2+ Overload Drives Skin Fibrosis via mtDNA Leakage and cGAS-STING Activation in Systemic Sclerosis.
To explore the clinical relevance of mitochondrial DNA (mtDNA) in systemic sclerosis (SSc) and elucidate the mechanism by which mtDNA leakage drives fibroblast activation. Plasma mtDNA was quantified by qPCR in 50 patients with SSc and 20 healthy controls (HC). Primary dermal fibroblasts from 5 diffuse cutaneous SSc (dcSSc) and 5 HC (n= 5 per group) were analyzed for mitochondrial structure, function and RNA-seq profiling. The opening of mitochondrial permeability transition pore (mPTP) and oligomerization of VDAC1 were examined with Ca2+ modulators and inhibitors. STING knockdown (siRNA) was performed for validation. The STING inhibitor H-151 was evaluated in vitro and in a bleomycin-induced skin fibrosis model (n= 6 mice per group). Plasma mtDNA levels were significanly higher in SSc than in HC, negatively correlating with forced vital capacity (FVC)% (r = -0.436, P < 0.01) , and correlating with modified Rodnan skin score (mRSS) ( r = 0.807, P < 0.001 ), IL-6 ( r = 0.667, P < 0.001 ) and TGF-β ( r = 0.678, P < 0.001 ). SSc fibroblasts exhibited abnormal mitochondrial morphology and dysfunction. Increased MCU and VDAC1 promoted mitochondrial Ca2+ overload, mPTP opening, VDAC1 oligomerization, cytosolic mtDNA accumulation, which activated the cGAS-STING pathway and triggered profibrotic responses. Pharmacologic blockade of mPTP or VDAC1 reduced cytosolic mtDNA, while H-151 suppressed profibrotic markers in SSc fibroblasts and attenuated dermal thickening and collagen deposition in bleomycin-treated mice. The Ca2+-mtDNA-cGAS/STING axis drives fibroblast activation and skin fibrosis in SSc, representing a promising therapeutic target.
cell therapies
2026-09-14 | Mesenchymal Stem Cell Therapy for Systemic Sclerosis: Current Evidence and Clinical Applications.
Systemic sclerosis is a multisystem autoimmune disease characterized by immune dysfunction, vasculopathy, and progressive fibrosis, yet current therapies rarely address these pathogenic axes simultaneously. Mesenchymal stem cell therapy has gained increasing interest as a disease-modifying strategy because its therapeutic activity appears to depend largely on paracrine signaling rather than durable engraftment. Through these mechanisms, mesenchymal stem cells may suppress profibrotic fibroblast activation, recalibrate innate and adaptive immune responses, and enhance vascular repair. Cell-free approaches, particularly extracellular vesicles and exosome-based therapeutics, are further expanding the translational potential of this field by offering scalable alternatives to live cell administration. Early clinical studies of systemic infusion and local delivery for complications such as hand dysfunction (reduced grip strength, joint contracture, and impaired fine motor function) and digital vasculopathy have demonstrated feasibility, acceptable short-term safety, and encouraging signals in skin and vascular outcomes. Nevertheless, long term clinical benefit remains uncertain because published studies are few and heterogeneous in cell source, manufacturing and expansion protocols, dose, route, concomitant therapy, and endpoint selection. Progress in this area will require standardized potency frameworks, improved control of senescence and functional drift, phenotype-specific trial stratification, and harmonized outcome hierarchies across vascular and cutaneous domains. Integration of immune and vascular biomarkers as pharmacodynamic readouts, together with multicenter randomized controlled trials and long-term follow-up, will be essential for defining efficacy and advancing targeted cell-free therapeutic platforms in systemic sclerosis.
2026-08-01 | Isolated Neck Extensor Myositis and Chest Wall Skin Thickening: Case Report of a Rare Initial Presentation of Systemic Sclerosis and Overlap Myositis
Background Systemic sclerosis is a multisystemic connective tissue characterized by immune dysregulation, fibrosis and vasculopathy. Skin thickening, a cardinal feature of this disease process, characteristically progresses in a centripetal pattern.[1] Overlap disease with idiopathic inflammatory myositis can be seen, classically involving weakness of the proximal muscle groups of the upper and lower limbs.[2] Case Report We report the case of a 46-year-old female referred for assessment of possible systemic sclerosis with a several month history of neck extensor weakness, Raynaud’s phenomenon, moderate skin thickening isolated to the chest, positive ANA 1:640 nucleolar, and elevated CK of 436. Over the next few months, she developed rapidly progressive and severe skin thickening of the proximal and distal extremities, face and hands with associated sclerodactyly. Advanced serological testing was negative for myositis or systemic sclerosis associated with autoantibodies. Baseline investigations including echocardiogram, pulmonary function test and high-resolution CT scan of the lungs were normal. MRI of the extremities and neck demonstrated mild edema to the posterior neck paraspinal muscles, EMG of the neck extensors was positive for irritable myopathy, and subsequent muscle biopsy of the cervical paraspinal muscles demonstrated marked fibrosis with end-stage muscle atrophy in keeping with partially treated myositis. Punch biopsies of the skin demonstrated sclerosing dermatitis. A diagnosis of diffuse cutaneous systemic sclerosis with overlap myositis was made. She was treated initially with methotrexate followed by mycophenolate, however due to rapidly progressive cutaneous disease she underwent autologous hematopoietic stem cell transplant approximately 8 months after initial presentation. With ongoing follow-up 6 months post-transplant, the patients’ skin thickening had significantly improved, her myositis and Raynaud’s phenomenon had resolved, and she remained in remission off all immunosuppressive therapies. Conclusion Isolated neck extensor myositis and initial skin thickening of the chest is a rare presentation of early diffuse cutaneous systemic sclerosis. This case highlights the importance of close follow up of patients with atypical disease manifestations and seeking histopathological correlation to assist in making a definitive diagnosis. References [1.] Volkmann E. Lancet 2022;401:304-18. [2.] Bhansing K. Arthritis Res Ther 2014;16:R111.
2026-06-27 | High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.
Purpose: The 2023 EULAR update recommends autologous hematopoietic stem-cell transplantation preceded by high-intensity immunosuppression (HI-IS/HSCT) for selected poor-prognosis early diffuse cutaneous systemic sclerosis (dcSSc). As real-world data remain scarce, we compared 5-year outcomes of HI-IS/HSCT recipients with propensity-matched controls receiving standard care. Because undergoing HI-IS/HSCT identifies poor-prognosis systemic sclerosis (SSc), we compared their 5-year outcomes with those of propensity-matched dcSSc controls receiving standard care. This retrospective multicenter study analyzed ACR/EULAR-2013 dcSSc patients treated after 2013 from the Greater Paris University Hospitals and French national registry. Patients had poor-prognosis SSc defined by early disease and rapid skin progression or organ involvement. HI-IS/HSCT recipients were matched 1:1 with conventional immunosuppression controls using nearest-neighbor 20-variable propensity scores (covering demographics, antibodies, organ involvement, and prior treatments). Outcomes included overall survival (OS), event-free survival (EFS), progression-free survival (PFS), and toxicities at 60 months. Exploratory multivariable logistic regression identified predictors of EFS. We analyzed 100 patients, equally divided between the HI-IS/HSCT and control groups. Five-year OS was similar (90%) in both groups. However, HI-IS/HSCT was associated with significantly improved 5-year event-free survival (76% vs 46%, p = 0.021) and progression-free survival (82% vs 40%, p = 0.001), a more favorable Global Rank Composite Score (p = 0.001), greater skin improvement (p < 0.001), and stabilization of FVC (p = 0.034) compared with controls. Prior DMARD burden was significantly lower in the transplant group (median 1 vs 2, p < 0.0001). Conditioning containing fludarabine/rituximab showed a non-significant trend towards higher EFS compared to CYC + ATG alone (82.6% vs 66.7%, p = 0.33). HI-IS/HSCT caused higher grade ≥4 toxicities (36% vs 8%, p < 0.001), with a 2% procedure-related mortality. Older age and pre-existing cardiac involvement were independently associated with worse EFS after transplant. In patients with poor-prognosis dcSSc, 5-year overall survival was high and similar between HI-IS/HSCT and modern conventional care. However, HI-IS/HSCT provided significantly superior event-free and progression-free survival, skin improvement, and pulmonary stabilization. These findings support early HSCT as a highly effective disease-stabilizing therapy in carefully selected patients, provided they undergo rigorous cardiac screening.
2026-06-01 | OC.56 Safety and early efficacy of rapcabtagene autoleucel, an autologous CD19-directed chimeric antigen receptor T-cell therapy, in severe refractory diffuse cutaneous systemic sclerosis
Introduction
Diffuse cutaneous systemic sclerosis (dcSSc) can be severe, with potential significant organ involvement, leading to end-organ failure and death. Therapeutic options for dcSSc are limited and inadequately address clinical manifestations or modify disease progression. CD19-targeted chimeric antigen receptor (CAR)-T cell therapy shows promise, with the potential to induce deep and sustained B cell depletion, thereby facilitating an immune system reset and offering the prospect of long-term remission in autoimmune diseases, including dcSSc.
Material and Methods
This Phase 2 open-label, AUTOGRAPH study (CYTB323K12201) evaluates rapcabtagene autoleucel, an autologous CD19-directed CAR-T cell therapy, in participants with severe, refractory (inadequate response to >2 prior systemic therapies) dcSSc. The study consists of two sequential cohorts: Cohort 1, a single-arm safety cohort, followed by a randomized and controlled Cohort 2. All participants in Cohort 1 underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by a single intravenous infusion of rapcabtagene autoleucel, with the initial three dosed sequentially with a 28-day observation period between participants; subsequent participants were dosed in parallel. All participants were hospitalized >=14 days post-infusion.
Results
Cohort 1 included 5 females and 1 male, with median: age of 49 years (range: 32–56), disease duration of 22 months (range: 10–35) and modified Rodnan skin score (mRSS) of 36.5 (range: 34–48); 5/6 participants were anti-Scl-70 positive and, 1/6 were anti-RNA polymerase 3 positive. All participants had progressive skin disease; two with concurrent progressive interstitial lung disease and one with clinically significant cardiac involvement. Participants treated with rapcabtagene autoleucel in Cohort 1 demonstrated rapid and profound B cell depletion following CAR-T expansion. Two participants with >=20 weeks of follow-up demonstrated a >=30% reduction in the mRSS along with stabilization or improvement in pulmonary function and were able to discontinue immunosuppressive therapies. Rapid improvements were noted in patient and physician global assessment and disability index. In all 3 participants with >=4 months of follow-up, circulating CD19 B cells reappeared 90 days post-infusion. Rapcabtagene autoleucel was well tolerated (table 1). All cases of cytokine release syndrome resolved without sequelae. No instances of immune effector cell-associated neurotoxicity syndrome were observed. Adverse events were manageable and aligned with the established safety profile of CAR-T cell therapies.
Conclusions
Preliminary data from Cohort 1 suggests a favorable safety profile, CAR-T cell expansion, B cell depletion and promising initial efficacy of rapcabtagene autoleucel in severe refractory dcSSc, supporting its continued evaluation.
Funding Statement
Novartis Pharma AG, Basel, Switzerland.
2026-06-01 | P.249 Efficacy of autologous hematopoietic stem cell transplantation in diffuse cutaneous systemic sclerosis: a case series linking outcomes to patient age and conditioning regimen
Introduction
Diffuse cutaneous systemic sclerosis (dcSSc) is a severe autoimmune disease characterized by progressive skin fibrosis and internal organ involvement. Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a potential therapeutic option for patients with refractory dcSSc following failure of conventional immunosuppressive treatments.
Material and Methods
This case series reports outcomes of three Thai patients with progressive dcSSc (aged 19, 52, and 35 years) who underwent AHSCT after failing standard therapies including methotrexate, mycophenolate mofetil, cyclophosphamide, and rituximab. The conditioning regimen consisted of fludarabine (30 mg/m2), cyclophosphamide (40-60 mg/m2), and anti-thymocyte globulin (2.5 mg/kg). Clinical outcomes were assessed using modified Rodnan skin score (mRSS) and monitoring for transplant-related complications.
Results
All patients achieved neutrophil engraftment within 7-9 days post-transplant. Two patients (aged 19 and 35) demonstrated sustained clinical improvement with dramatic mRSS reductions from 29 to 4 and 20 to 4, respectively. The older patient (aged 52) showed initial improvement (mRSS 32 to 15) but experienced early relapse with progression of myocarditis within two months. Complications included cytomegalovirus reactivation in all cases, Epstein-Barr virus reactivation, drug-induced liver injury, and one case of disseminated Mycobacterium malmoense infection, all successfully managed.
Conclusions
AHSCT can achieve significant clinical improvement in selected patients with refractory dcSSc, particularly younger individuals without severe cardiac involvement. The reduced cyclophosphamide dose (40 mg/m2) may have contributed to early relapse in the older patient, highlighting the importance of individualized conditioning intensity and careful patient selection for optimal outcomes.
antibodies
2026-09-28 | Rituximab in diffuse cutaneous systemic sclerosis: Assessing safety and therapeutic outcomes
Background: Diffuse cutaneous systemic sclerosis (dcSSc) is a severe autoimmune connective tissue disease characterised by progressive skin fibrosis, vasculopathy, and internal organ involvement. Conventional immunosuppressive therapies often provide suboptimal control of skin fibrosis. Rituximab, a B-cell-depleting monoclonal antibody, has emerged as a potential disease-modifying therapy in systemic sclerosis.Aims and Objectives: To evaluate the safety and therapeutic efficacy of rituximab in patients with diffuse cutaneous systemic sclerosis.Materials and Methods: This prospective, single-centre observational study was conducted in the Department of Dermatology, ANMMCH, Gaya. Eleven adult patients with dcSSc and Modified Rodnan Skin Score (MRSS) ≥ 10 were enrolled and treated with Inj. Rituximab 1000mg iv on day 1 and day 14 according to standard therapeutic protocols. Patients were followed monthly for six months. Clinical assessment included MRSS, mouth opening, Raynaud’s phenomenon, dyspnea, dysphagia, Ingram sign, Barnett sign, and salt-and-pepper pigmentation. Statistical analysis was performed using SPSS version 26.0, with significance set at p
2026-08-20 | Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis.
Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7-expressing cytotoxic T cells implicated in diffuse cutaneous SSc. In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months one, three, and six. Flow cytometry quantified CD4+CD319+ and CD8+CD319+ T cells, cytotoxic and activation markers, and stimulated intracellular interleukin-4 (IL-4), IL-17A, and interferon-γ (IFN-γ). Analyses compared abatacept-treated molecular endotypes with placebo and related immune changes to modified Rodnan skin score (mRSS) change. Skin single-cell RNA sequencing included five healthy controls and eight patients with SSc. At baseline, CD319+ T cells showed greater cytokine production, activation, and granzyme and perforin expression than CD319- T cells in 60 evaluable participants (P < 0.001 to P < 0.0001). Abatacept reduced CD4+CD319+ and CD8+CD319+ T cell frequencies at month six; placebo did not. Effects were strongest in patients in the fibroproliferative group, in whom CD8+CD319+ T cells decreased versus placebo (n = 7 versus n = 36; P = 0.0377). In this endotype, abatacept reduced IL-4 in CD4+CD319+ and CD8+CD319+ T cells at month three (P = 0.0468 and P = 0.0287) and IL-17A in CD8+CD319+ T cells at month six (P = 0.0004), whereas IFN-γ was unchanged. Reduction in CD4+CD319+ T cells correlated with mRSS improvement in abatacept-treated patients (r = 0.5297, P = 0.0423). Skin single-cell RNA sequencing showed increased SLAMF7 expression in SSc T cells (P = 0.017), enriched within cytotoxic subsets. CD319+ T cells represent highly differentiated, activated cytotoxic effector populations in SSc. Abatacept selectively modulates these cells and suppresses associated profibrotic and proinflammatory cytokines, particularly in the fibroproliferative subtype, in which CD319+ T cell reductions correlate with clinical improvement.
2026-08-02 | Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey.
To evaluate contemporary global treatment of diffuse cutaneous systemic sclerosis (dcSSc) skin by SSc specialists. An anonymous survey was distributed via the Scleroderma Clinical Trials Consortium, European Scleroderma Trials and Research Group (EUSTAR), and Collaborative National Quality and Efficacy Registry (CONQUER) distribution lists between June and September 2025. The survey comprised four sections: Demographics, Treatment of dcSSc Skin, Impact of Recent Guidelines, and Clinical Trials. Responses included 103 physicians (93 completed): 43% North America, 31% Europe, 15% South America and 12% elsewhere. The majority practice within an SSc centre (80%) and participate in clinical trials (84%). Mycophenolate mofetil (MMF) was preferred first-line treatment (71%) for dcSSc without ILD, rising to 92% for dcSSc with mild/non-progressive ILD. For active skin involvement despite MMF, trial referral was preferred as next step irrespective of ILD (59% without ILD and 58% with ILD). Treatment preferences have evolved, with 40% increasing MMF use and 47% decreasing methotrexate use, over the previous 2-3 years. Biologic use has increased, with 56% and 37% reporting increasing rituximab and tocilizumab use, respectively. For dcSSc without ILD, 85% have prescribed rituximab, and 65% have prescribed tocilizumab. Biologic availability has impacted trial enrolment (73% agreement). Treatment decision-making for dcSSc skin involvement has been materially influenced by recent BSR and/or EULAR guidelines (43% agreement). MMF is preferred first-line for dcSSc. In the absence of compelling scientific justification for combination or step-up immunomodulatory approaches, trial referral is currently the preferred next treatment option. Biologic use is increasing, which impacts trial enrolment.
2026-06-19 | Efficacy of different pharmacological therapies for diffuse cutaneous systemic sclerosis: a systematic review and network meta-analysis.
This study aims to compare the effectiveness of different pharmacological therapies for diffuse cutaneous systemic sclerosis (dcSSc) through a network meta-analysis (NMA). Randomized controlled trials (RCTs) on pharmacological interventions for dcSSc were systematically searched in PubMed, Embase, Cochrane Library, and Web of Science up to 2026. A Bayesian network meta-analysis was carried out using Markov Chain Monte Carlo (MCMC) methods via R software and its GeMtc package. Outcomes assessed included Modified Rodnan Skin Score (MRSS), pulmonary functions (forced vital capacity [FVC], and diffusing capacity of the lung for carbon monoxide [DLCO]), and Health Assessment Questionnaire (HAQ). Effect sizes were reported as standardized mean differences (SMDs) with corresponding 95% credible intervals (95% CrIs). A total of 20 RCTs involving 1,760 patients and 16 interventions were included. The results revealed that rituximab was the most effective intervention for reducing MRSS (SMD = - 3.4, 95% CrI (- 4.2, - 2.7)), followed by cyclophosphamide (CTX) (SMD = - 2.8, (- 3.3, - 2.2)), and belimumab (SMD = - 1.5, (- 2.5, - 0.39)). Belimumab (SMD = 1.9, (0.75, 3.1)) and CTX (SMD = 1.3, (0.86, 1.8)) topped FVC improvement. Methotrexate (MTX) was the most effective for enhancing DLCO (SMD = 0.52, (0.046, 0.99)). Belimumab (HAQ: SMD = - 3.8, (- 5.5, - 2.1)) and CTX (HAQ: SMD = - 2.9, (- 3.4, - 2.3)) were significantly effective in lowering HAQ scores. B-cell-targeted therapies (e.g., rituximab and belimumab) seemed to outperform other therapeutic agents in lowering MRSS and HAQ scores. Conventional immunosuppressants (e.g., CTX and MTX) might be more effective in enhancing pulmonary functions. Treatment strategies should be tailored according to the extent and severity of organ involvement.
2026-06-10 | Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.
Tocilizumab (TCZ) has shown beneficial effects on interstitial lung disease (ILD) in systemic sclerosis (SSc). We aimed to assess the real-life safety and effectiveness of TCZ on several SSc-related domains using data from a French-Italian multicentre cohort. We conducted a retrospective analysis of patients with SSc treated with TCZ across 15 referral centres. The following clinical data were collected at 12 months before TCZ initiation, at baseline and at 12 and 24 months of treatment: modified Rodnan skin score (mRSS), pulmonary function tests, Disease Activity Score in 28 joints using C reactive protein, digital ulcers and cardiac biomarkers. ILD progression was defined as a decline ≥5 in %predicted forced vital capacity (%pFVC) over 12±3 months. 197 patients were included (88% female; median age 57 years; median disease duration 9 years); 67% were antitopoisomerase I positive. TCZ monotherapy was used in 29% of cases, methotrexate was the most frequent combined treatment (35%). In SSc-associated ILD, %pFVC declined significantly from -12 months to baseline (81% to 77%; p=0.003). On TCZ introduction, %pFVC stabilised and the proportion of progressors declined from 43% to 24% (p=0.015). Among diffuse cutaneous patients, mRSS decreased significantly at 12 and 24 months. Digital ulcers, arthritis activity and cardiac biomarkers also improved. Infections were the most frequent adverse events (22.8%). TCZ was discontinued in 32% of patients, mainly for inefficacy. Pulmonary arterial hypertension and older age predicted TCZ failure, whereas elevated CRP predicted better response. In this large real-life cohort, TCZ was safe and associated with consistent benefits across different domains, supporting its role as a potential disease-modifying treatment in selected patients with SSc.
other
2026-06-10 | High mobility group motif proteins' role in fibrosis, inflammation, and vascular injury in systemic sclerosis.
Systemic Sclerosis (SSc) is an idiopathic systemic autoimmune disease characterized by progressive cutaneous and systemic fibrosis, severe vasculopathy, and multiple humoral and cellular immunological alterations. The pathogenesis of SSc is highly complex and remains incompletely elucidated. The fibrotic process is a crucial component of SSc and is responsible for organ failure and high mortality. Although an increasing understanding of the fibrotic process has enabled the clinical development of antifibrotic therapeutic agents, these agents have limited clinical efficacy. Recently, the potential role of a group of transcription factors containing a High Mobility Group (HMG) motif, in the development and pathological manifestations of SSc has been postulated. HMG proteins (notably HMGB1 and SOX9) act as profibrotic and proinflammatory transcription factors; however, HMG proteins can also function as damage-associated molecular patterns, amplifying Toll-like receptors and RAGE signaling, promoting endothelial activation, leukocyte recruitment, and stimulating the production of profibrotic cytokines. This convergent role of HMG proteins across various aspects of SSc pathogenesis, including immune dysregulation, vasculopathy, and fibrosis, makes them among the most attractive novel regulators and a desirable therapeutic target for SSc. Here, we review the recent evidence on the role of HMG proteins in SSc pathogenesis and explore the potential role of inhibiting their function.
2025-09-08 | Overlapping Connective Tissue Disease-Polymyositis and Diffuse Systemic Scleroderma: A Case Report.
Polymyositis with concomitant scleroderma is a rare, progressive condition with profound consequences if not addressed promptly. Severity and symptom presentation varies between patients, and much is unknown about how best to treat overlapping connective tissue diseases. This case discusses the rare presentation, medical evaluation, and successful treatment of a 46-year-old woman with excessive muscle atrophy, weakness, and tissue fibrosis, who was diagnosed with overlapping connective tissue disorder after extensive work up that included a muscle biopsy, skin punch biopsy, and autoantibody lab work. This patient recovered well with the use of mycophenolate mofetil demonstrating promising results for similar patients and offering insight into potential methods of evaluation and medical management. Studying cases like this one give providers more knowledge about overlapping connective tissue disease and how to best diagnose and manage them.
2025-06-26 | Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis.
Background/Objectives: Systemic sclerosis (SSc) is a progressive autoimmune disease characterized by widespread fibrosis, including skin thickening. Mycophenolate mofetil (MMF) is commonly used in SSc-associated interstitial lung disease, but its efficacy in improving skin fibrosis has not been systematically evaluated. This study aimed to assess the therapeutic effect of MMF on cutaneous sclerosis in SSc, as measured by the modified Rodnan skin score (mRSS). Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. PubMed, Embase, and Web of Science were searched from January 2000 to March 2025. Studies reporting mRSS outcomes in SSc patients treated with MMF were included, provided that the effect of MMF could be separately evaluated when used alongside other therapies. Risk of bias was assessed using the Cochrane RoB 2.0 tool for randomized controlled trials and the ROBINS-I tool for non-randomized studies. A random-effects model was used to estimate the pooled mean change in mRSS. Heterogeneity and publication bias were evaluated. Results: Eight studies involving 569 patients were included. The pooled mean reduction in mRSS following MMF treatment was -5.82 (95% CI: -7.46 to -4.19), exceeding the minimal clinically important difference. Heterogeneity across studies was substantial (I2 = 82.6%). A post hoc exploratory subgroup analysis suggested greater improvement in early disease (<2 years), though this finding requires confirmation in prospective studies. MMF was generally well tolerated, with low discontinuation rates due to adverse events. Conclusions: MMF is associated with a statistically and clinically significant improvement in skin fibrosis in patients with SSc. These findings support its use as a frontline therapy for progressive cutaneous involvement, although further prospective studies are needed to identify optimal candidates for treatment.
2025-05-12 | Full Recovery Over One Year of the Overlap Syndrome Scleromyositis to Maintenance Therapy with Mycophenolate Mofetil and Rituximab, which Relapsed within 8 Months of Discontinuation.
Scleromyositis (SM) is an emerging, distinct entity within the spectrum of diffuse systemic sclerosis (SSc) and autoimmune inflammatory myopathies. It can carry a poorer prognosis due to multisystem involvement and extramuscular complications, with no consensus on treatment strategies currently available. We report on a 20-year-old woman with a history of recurrent infections over the past year, who presented with persistent myalgias for four months. On examination, she exhibited muscle weakness in the scapular and pelvic girdles, along with sclerodactyly. Laboratory results showed elevated creatine kinase (13,000 U/l), aldolase (15.6 U/l), lactate dehydrogenase (1,481 U/l) and myoglobin (4,400 ng/ml). Autoimmune screening was positive for antinuclear antibodies, anti-PM-scleroderma (anti-PM-Scl) 75 and 100, and anti-CENP-B antibodies. An MRI of the pelvic girdle indicated acute/subacute myositis, and electromyography revealed both distal and proximal myopathy. Muscle biopsy showed extensive necrosis with minimal inflammatory infiltration. Nailfold capillaroscopy demonstrated an early scleroderma pattern, while CT and spirometry revealed mild interstitial restrictive lung disease. Initial treatment involved intravenous immunoglobulin (IVIG), mycophenolate mofetil (MMF) and prednisolone. This was followed by maintenance therapy with MMF and rituximab (RTX) every six months for the first year. Over six months, the patient showed progressive improvement in muscle strength and normalisation of muscle enzyme levels. In conclusion, SM presents with variable phenotypes, ranging from mild to extensive systemic involvement. This case underscores the importance of individualised patient stratification and highlights the need for structured induction and maintenance therapy due to the disease's extensive activity. Scleromyositis (SM) is a rare and poorly understood condition that combines features of systemic sclerosis and immune-mediated myositis, often linked to anti-PM-scleroderma antibodies.Despite efforts to classify SM, it demonstrates unique clinical patterns that distinguish it from other myositis subtypes.The management of SM remains challenging, as there are no established guidelines or standardised treatment protocols.
2023-06-20 | Regulation of MicroRNA Expression in Scleroderma and Idiopathic Pulmonary Fibrosis: A Research Study
Introduction: Scleroderma (SSc) is an autoimmune disorder with the hallmark of fibrosis of the skin, vasculature and internal organs. Patients with SSc and undifferentiated connective tissue disease (UCTD) are susceptible to interstitial lung disease (ILD), leading to decreased lung function and death. Idiopathic pulmonary fibrosis (IPF) is a form of ILD that is not associated with extrapulmonary manifestations. In this study, lung involvement of SSc was studied by observing how disease progression and pathogenesis differ among patients with SSc, UCTD, and ILD compared to healthy controls and patients with IPF. Our group has previously identified disease targets through microRNA sequencing, including the DICER enzyme, which works closely with the protein DGCR8 and the enzyme DROSHA in the RNA interference pathway. The canonical pathway stipulates that DICER processes microRNAs in the cytosol while DGCR8 and DROSHA process microRNAs in the nucleus. DICER, DROSHA, and DGCR8 are hypothesized to contribute to ILD progression. Methods: Human peripheral blood mononuclear cells (PBMCs) were isolated from voluntary participants, including healthy controls. PBMCs were subsequently lysed with subcellular fractionation buffer. Western blotting was done on the resulting cytosolic and nucleic fractions for DICER, DROSHA, and DGCR8 protein expression. The cytosolic fractions were normalized to GAPDH, while the nucleic fractions were normalized to B2M. Nonparametric Kruskal‐Wallis tests were used for statistical analysis. Results: The medians were significantly higher for healthy controls for DICER in the nucleus with a p-value of 0.0302, and DROSHA in the cytosol with a p-value of 0.0406 compared to patients with SSc, UCTD, and IPF. Discussion: Differences in expression were found for DROSHA in the cytosol and DICER in the nucleus, suggesting dysregulation of the non-canonical RNA interference pathways in SSc, UCTD, and IPF patients. Variability of disease progression within the groups could lead to variable enzyme and protein levels within the same disease status. With larger sample sizes, statistically insignificant differences would become significant. Lipid nanoparticle technology could be used to deliver deficient microRNAs to silence mRNA in patients. Conclusion: Due to dysregulation of the RNA interference pathway, microRNAs may be inadequately processed in the patient groups.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
8 orphan drug designations for Diffuse cutaneous systemic sclerosis.
8 orphan drug designations for Diffuse cutaneous systemic sclerosis.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
botulinum toxin type A (BTX-A) | proteins | FDA | ARCK Biologics, INC. | |
(2R)-3-(4-{[4-Chloro-2-(difluoromethoxy)phenyl]carbamoyl}-4-[5-(propan-2-yl)-1H-pyrazol-1-yl]piperidin-1-yl)-2-(oxan-4-yl)propanoic acid hydrochloride, upadacitinib | small molecules | EMA | AbbVie Deutschland GmbH & Co. KG | |
nerandomilast | small molecules | FDA | Boehringer Ingelheim Pharmaceuticals, Inc, (BIPI) | |
nemolizumab | antibodies | FDA | Galderma Research and Development, LLC | |
autologous CD3+ T cells expressing CD19 chimeric antigen receptor | cell therapies | FDA | — | Juno Therapeutics, Inc., a subsidiary of Bristol Myers Squibb |
Resecabtagene autoleucel | cell therapies | EMA | Cabaletta Bio (Germany) GmbH | |
blinatumomab | antibodies | FDA | Amgen Inc. | |
8-methoxsalen | small molecules | FDA | Therakos Development Limited |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.